WO2023044509A1 - Process for making cysteine protease inhibitors and compounds provided by that process - Google Patents
Process for making cysteine protease inhibitors and compounds provided by that process Download PDFInfo
- Publication number
- WO2023044509A1 WO2023044509A1 PCT/US2022/076742 US2022076742W WO2023044509A1 WO 2023044509 A1 WO2023044509 A1 WO 2023044509A1 US 2022076742 W US2022076742 W US 2022076742W WO 2023044509 A1 WO2023044509 A1 WO 2023044509A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- salt
- methyl
- group
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 207
- 238000000034 method Methods 0.000 title claims abstract description 75
- 230000008569 process Effects 0.000 title claims abstract description 63
- 239000002852 cysteine proteinase inhibitor Substances 0.000 title description 2
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- 150000003839 salts Chemical class 0.000 claims description 57
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 45
- -1 tetrafluoroborate Chemical compound 0.000 claims description 40
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 14
- 150000002367 halogens Chemical class 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical group CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 11
- 230000002862 amidating effect Effects 0.000 claims description 11
- 230000008878 coupling Effects 0.000 claims description 11
- 238000010168 coupling process Methods 0.000 claims description 11
- 238000005859 coupling reaction Methods 0.000 claims description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims description 7
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 7
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical group CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- XGUXJMWPVJQIHI-YFKPBYRVSA-N (2s)-2-azaniumyl-3-cyclopropylpropanoate Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1CC1 XGUXJMWPVJQIHI-YFKPBYRVSA-N 0.000 claims description 5
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 claims description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 230000002140 halogenating effect Effects 0.000 claims description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- XGUXJMWPVJQIHI-UHFFFAOYSA-N S-cyclopropylalanine Natural products OC(=O)C(N)CC1CC1 XGUXJMWPVJQIHI-UHFFFAOYSA-N 0.000 claims description 4
- 239000006184 cosolvent Substances 0.000 claims description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 3
- 125000001246 bromo group Chemical group Br* 0.000 claims description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- XBNGYFFABRKICK-UHFFFAOYSA-M 2,3,4,5,6-pentafluorophenolate Chemical compound [O-]C1=C(F)C(F)=C(F)C(F)=C1F XBNGYFFABRKICK-UHFFFAOYSA-M 0.000 claims description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 125000003566 oxetanyl group Chemical group 0.000 claims description 2
- 108091005804 Peptidases Proteins 0.000 abstract description 21
- 239000004365 Protease Substances 0.000 abstract description 21
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract description 18
- 102000035195 Peptidases Human genes 0.000 abstract description 3
- 150000002825 nitriles Chemical class 0.000 abstract description 3
- 239000011541 reaction mixture Substances 0.000 description 40
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 35
- 239000000203 mixture Substances 0.000 description 35
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 239000010410 layer Substances 0.000 description 26
- 238000006243 chemical reaction Methods 0.000 description 24
- 125000003118 aryl group Chemical group 0.000 description 20
- 241000711573 Coronaviridae Species 0.000 description 19
- 125000004432 carbon atom Chemical group C* 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- 125000000623 heterocyclic group Chemical group 0.000 description 18
- 239000012044 organic layer Substances 0.000 description 18
- 238000003786 synthesis reaction Methods 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- 125000000217 alkyl group Chemical group 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 15
- KTOOVWCZIOIVDS-UWVGGRQHSA-N methyl (2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-[(3S)-2-oxopiperidin-3-yl]propanoate Chemical compound C(C)(C)(C)OC(=O)N[C@H](C(=O)OC)C[C@H]1C(NCCC1)=O KTOOVWCZIOIVDS-UWVGGRQHSA-N 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 235000019439 ethyl acetate Nutrition 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 125000001424 substituent group Chemical group 0.000 description 13
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 12
- 125000005842 heteroatom Chemical group 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 239000012298 atmosphere Substances 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 150000003254 radicals Chemical group 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- BNMFQWUHWYJTRI-BQFCYCMXSA-N 7-chloro-N-[(2S)-1-[[(1S)-1-cyano-2-[(3S)-2-oxopiperidin-3-yl]ethyl]amino]-3-cyclopropyl-1-oxopropan-2-yl]-1H-indole-2-carboxamide Chemical compound ClC=1C=CC=C2C=C(NC=12)C(=O)N[C@H](C(=O)N[C@@H](C[C@H]1C(NCCC1)=O)C#N)CC1CC1 BNMFQWUHWYJTRI-BQFCYCMXSA-N 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- CZKZGEDUHKXUKJ-IEZWGBDMSA-N methyl (2S)-2-[[(2S)-2-[(7-chloro-1H-indole-2-carbonyl)amino]-3-cyclopropylpropanoyl]amino]-3-[(3S)-2-oxopiperidin-3-yl]propanoate Chemical compound COC([C@H](C[C@H](CCCN1)C1=O)NC([C@H](CC1CC1)NC(C1=CC2=CC=CC(Cl)=C2N1)=O)=O)=O CZKZGEDUHKXUKJ-IEZWGBDMSA-N 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000012065 filter cake Substances 0.000 description 6
- 125000001072 heteroaryl group Chemical group 0.000 description 6
- 150000002430 hydrocarbons Chemical class 0.000 description 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- BXVXEOBIHITAAK-XIRDDKMYSA-N N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-[(3S)-2-oxopiperidin-3-yl]propan-2-yl]amino]-3-cyclopropyl-1-oxopropan-2-yl]-7-chloro-1H-indole-2-carboxamide Chemical compound NC([C@H](C[C@H]1C(NCCC1)=O)NC([C@H](CC1CC1)NC(=O)C=1NC2=C(C=CC=C2C=1)Cl)=O)=O BXVXEOBIHITAAK-XIRDDKMYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 125000002837 carbocyclic group Chemical group 0.000 description 5
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 5
- 125000001188 haloalkyl group Chemical group 0.000 description 5
- 229930195733 hydrocarbon Natural products 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 239000012299 nitrogen atmosphere Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- QPLOPNRBTYZIIG-QWRGUYRKSA-N dimethyl (2S,4S)-2-(2-cyanoethyl)-4-[(2-methylpropan-2-yl)oxycarbonylamino]pentanedioate Chemical compound COC(=O)[C@@H](CCC#N)C[C@H](NC(=O)OC(C)(C)C)C(=O)OC QPLOPNRBTYZIIG-QWRGUYRKSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000013038 irreversible inhibitor Substances 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 230000000707 stereoselective effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 101710200092 Replicase polyprotein Proteins 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 238000006664 bond formation reaction Methods 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthene Chemical compound C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002427 irreversible effect Effects 0.000 description 3
- BMMICNDLOITWKA-BQBZGAKWSA-N methyl (2S)-2-amino-3-[(3S)-2-oxopiperidin-3-yl]propanoate Chemical compound COC(=O)[C@@H](N)C[C@@H]1CCCNC1=O BMMICNDLOITWKA-BQBZGAKWSA-N 0.000 description 3
- 239000013037 reversible inhibitor Substances 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 101800000504 3C-like protease Proteins 0.000 description 2
- 101800000535 3C-like proteinase Proteins 0.000 description 2
- 101800002396 3C-like proteinase nsp5 Proteins 0.000 description 2
- IGYVRRVRBQUTEF-UHFFFAOYSA-N 7-chloro-1h-indole-2-carbonyl chloride Chemical compound C1=CC(Cl)=C2NC(C(=O)Cl)=CC2=C1 IGYVRRVRBQUTEF-UHFFFAOYSA-N 0.000 description 2
- NVKAHBFPKVINGE-UHFFFAOYSA-N 7-chloro-1h-indole-2-carboxylic acid Chemical compound C1=CC(Cl)=C2NC(C(=O)O)=CC2=C1 NVKAHBFPKVINGE-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 102000005927 Cysteine Proteases Human genes 0.000 description 2
- 108010005843 Cysteine Proteases Proteins 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 101800004803 Papain-like protease Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 241000315672 SARS coronavirus Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000008484 agonism Effects 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 125000005206 alkoxycarbonyloxymethyl group Chemical group 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 239000012455 biphasic mixture Substances 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- WDECIBYCCFPHNR-UHFFFAOYSA-N chrysene Chemical compound C1=CC=CC2=CC=C3C4=CC=CC=C4C=CC3=C21 WDECIBYCCFPHNR-UHFFFAOYSA-N 0.000 description 2
- VPUGDVKSAQVFFS-UHFFFAOYSA-N coronene Chemical compound C1=C(C2=C34)C=CC3=CC=C(C=C3)C4=C4C3=CC=C(C=C3)C4=C2C3=C1 VPUGDVKSAQVFFS-UHFFFAOYSA-N 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- QNSPKWUAZQIIGZ-QMMMGPOBSA-N dimethyl (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanedioate Chemical compound COC(=O)CC[C@@H](C(=O)OC)NC(=O)OC(C)(C)C QNSPKWUAZQIIGZ-QMMMGPOBSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- GBROPGWFBFCKAG-UHFFFAOYSA-N picene Chemical compound C1=CC2=C3C=CC=CC3=CC=C2C2=C1C1=CC=CC=C1C=C2 GBROPGWFBFCKAG-UHFFFAOYSA-N 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 229940086542 triethylamine Drugs 0.000 description 2
- AQQXONIFJQMESP-IUCAKERBSA-N (2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-[(3S)-2-oxopiperidin-3-yl]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](C[C@@H]1CCCNC1=O)C(O)=O AQQXONIFJQMESP-IUCAKERBSA-N 0.000 description 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- 125000005848 1-(alkoxycarbonyloxy)ethyl group Chemical group 0.000 description 1
- NQRLUVCEUCAHST-UHFFFAOYSA-N 1-chloroindole-2-carboxylic acid Chemical compound C1=CC=C2N(Cl)C(C(=O)O)=CC2=C1 NQRLUVCEUCAHST-UHFFFAOYSA-N 0.000 description 1
- 125000005849 1-methyl-1-(alkoxycarbonyloxy)ethyl group Chemical group 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- XWIYUCRMWCHYJR-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine Chemical compound C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- WYZZNMWIWHRXRM-UHFFFAOYSA-N 2,8-diazaspiro[4.5]decane Chemical compound C1NCCC21CCNCC2 WYZZNMWIWHRXRM-UHFFFAOYSA-N 0.000 description 1
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- CQZIEDXCLQOOEH-UHFFFAOYSA-N 3-bromopropanenitrile Chemical compound BrCCC#N CQZIEDXCLQOOEH-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 1
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 1
- 229940125673 3C-like protease inhibitor Drugs 0.000 description 1
- 101800001631 3C-like serine proteinase Proteins 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108700023418 Amidases Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 241000288673 Chiroptera Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 101000982010 Homo sapiens Myelin proteolipid protein Proteins 0.000 description 1
- 101001126414 Homo sapiens Proteolipid protein 2 Proteins 0.000 description 1
- 244000309467 Human Coronavirus Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101001129124 Mannheimia haemolytica Outer membrane lipoprotein 1 Proteins 0.000 description 1
- 101001129122 Mannheimia haemolytica Outer membrane lipoprotein 2 Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 1
- 102100026784 Myelin proteolipid protein Human genes 0.000 description 1
- 125000005850 N-(alkoxycarbonyl)aminomethyl group Chemical group 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 101800000515 Non-structural protein 3 Proteins 0.000 description 1
- 101800000508 Non-structural protein 5 Proteins 0.000 description 1
- 101000761187 Odontomachus monticola U-poneritoxin(01)-Om1a Proteins 0.000 description 1
- 101000642171 Odontomachus monticola U-poneritoxin(01)-Om2a Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 101800002227 Papain-like protease nsp3 Proteins 0.000 description 1
- 101800001074 Papain-like proteinase Proteins 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 102100030486 Proteolipid protein 2 Human genes 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 101150052863 THY1 gene Proteins 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- SLGBZMMZGDRARJ-UHFFFAOYSA-N Triphenylene Natural products C1=CC=C2C3=CC=CC=C3C3=CC=CC=C3C2=C1 SLGBZMMZGDRARJ-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 208000035472 Zoonoses Diseases 0.000 description 1
- QVXFGVVYTKZLJN-KHPPLWFESA-N [(z)-hexadec-7-enyl] acetate Chemical compound CCCCCCCC\C=C/CCCCCCOC(C)=O QVXFGVVYTKZLJN-KHPPLWFESA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- JDPAVWAQGBGGHD-UHFFFAOYSA-N aceanthrylene Chemical group C1=CC=C2C(C=CC3=CC=C4)=C3C4=CC2=C1 JDPAVWAQGBGGHD-UHFFFAOYSA-N 0.000 description 1
- 125000004054 acenaphthylenyl group Chemical group C1(=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- SQFPKRNUGBRTAR-UHFFFAOYSA-N acephenanthrylene Chemical group C1=CC(C=C2)=C3C2=CC2=CC=CC=C2C3=C1 SQFPKRNUGBRTAR-UHFFFAOYSA-N 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- HXGDTGSAIMULJN-UHFFFAOYSA-N acetnaphthylene Natural products C1=CC(C=C2)=C3C2=CC=CC3=C1 HXGDTGSAIMULJN-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 102000005922 amidase Human genes 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- KNNXFYIMEYKHBZ-UHFFFAOYSA-N as-indacene Chemical compound C1=CC2=CC=CC2=C2C=CC=C21 KNNXFYIMEYKHBZ-UHFFFAOYSA-N 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 125000004452 carbocyclyl group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000005643 gamma-butyrolacton-4-yl group Chemical group 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 125000001976 hemiacetal group Chemical group 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 125000005241 heteroarylamino group Chemical group 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- QSQIGGCOCHABAP-UHFFFAOYSA-N hexacene Chemical compound C1=CC=CC2=CC3=CC4=CC5=CC6=CC=CC=C6C=C5C=C4C=C3C=C21 QSQIGGCOCHABAP-UHFFFAOYSA-N 0.000 description 1
- PKIFBGYEEVFWTJ-UHFFFAOYSA-N hexaphene Chemical compound C1=CC=C2C=C3C4=CC5=CC6=CC=CC=C6C=C5C=C4C=CC3=CC2=C1 PKIFBGYEEVFWTJ-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002062 molecular scaffold Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000002560 nitrile group Chemical group 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- PFTXKXWAXWAZBP-UHFFFAOYSA-N octacene Chemical compound C1=CC=CC2=CC3=CC4=CC5=CC6=CC7=CC8=CC=CC=C8C=C7C=C6C=C5C=C4C=C3C=C21 PFTXKXWAXWAZBP-UHFFFAOYSA-N 0.000 description 1
- OVPVGJFDFSJUIG-UHFFFAOYSA-N octalene Chemical compound C1=CC=CC=C2C=CC=CC=CC2=C1 OVPVGJFDFSJUIG-UHFFFAOYSA-N 0.000 description 1
- WTFQBTLMPISHTA-UHFFFAOYSA-N octaphene Chemical compound C1=CC=C2C=C(C=C3C4=CC5=CC6=CC7=CC=CC=C7C=C6C=C5C=C4C=CC3=C3)C3=CC2=C1 WTFQBTLMPISHTA-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- LSQODMMMSXHVCN-UHFFFAOYSA-N ovalene Chemical compound C1=C(C2=C34)C=CC3=CC=C(C=C3C5=C6C(C=C3)=CC=C3C6=C6C(C=C3)=C3)C4=C5C6=C2C3=C1 LSQODMMMSXHVCN-UHFFFAOYSA-N 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- PMJHHCWVYXUKFD-UHFFFAOYSA-N penta-1,3-diene Chemical compound CC=CC=C PMJHHCWVYXUKFD-UHFFFAOYSA-N 0.000 description 1
- SLIUAWYAILUBJU-UHFFFAOYSA-N pentacene Chemical compound C1=CC=CC2=CC3=CC4=CC5=CC=CC=C5C=C4C=C3C=C21 SLIUAWYAILUBJU-UHFFFAOYSA-N 0.000 description 1
- GUVXZFRDPCKWEM-UHFFFAOYSA-N pentalene Chemical compound C1=CC2=CC=CC2=C1 GUVXZFRDPCKWEM-UHFFFAOYSA-N 0.000 description 1
- JQQSUOJIMKJQHS-UHFFFAOYSA-N pentaphene Chemical compound C1=CC=C2C=C3C4=CC5=CC=CC=C5C=C4C=CC3=CC2=C1 JQQSUOJIMKJQHS-UHFFFAOYSA-N 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 125000002080 perylenyl group Chemical group C1(=CC=C2C=CC=C3C4=CC=CC5=CC=CC(C1=C23)=C45)* 0.000 description 1
- CSHWQDPOILHKBI-UHFFFAOYSA-N peryrene Natural products C1=CC(C2=CC=CC=3C2=C2C=CC=3)=C3C2=CC=CC3=C1 CSHWQDPOILHKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NQFOGDIWKQWFMN-UHFFFAOYSA-N phenalene Chemical compound C1=CC([CH]C=C2)=C3C2=CC=CC3=C1 NQFOGDIWKQWFMN-UHFFFAOYSA-N 0.000 description 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- DIJNSQQKNIVDPV-UHFFFAOYSA-N pleiadene Chemical compound C1=C2[CH]C=CC=C2C=C2C=CC=C3[C]2C1=CC=C3 DIJNSQQKNIVDPV-UHFFFAOYSA-N 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 150000003140 primary amides Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- LNKHTYQPVMAJSF-UHFFFAOYSA-N pyranthrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC3=C(C=CC=C4)C4=CC4=CC=C1C2=C34 LNKHTYQPVMAJSF-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- FMKFBRKHHLWKDB-UHFFFAOYSA-N rubicene Chemical compound C12=CC=CC=C2C2=CC=CC3=C2C1=C1C=CC=C2C4=CC=CC=C4C3=C21 FMKFBRKHHLWKDB-UHFFFAOYSA-N 0.000 description 1
- WEMQMWWWCBYPOV-UHFFFAOYSA-N s-indacene Chemical compound C=1C2=CC=CC2=CC2=CC=CC2=1 WEMQMWWWCBYPOV-UHFFFAOYSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000006337 tetrafluoro ethyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000005580 triphenylene group Chemical group 0.000 description 1
- 230000036967 uncompetitive effect Effects 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000007485 viral shedding Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
- 244000059546 zoonotic virus Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Definitions
- Coronaviridae family of viruses are enveloped, single-stranded, positive-sense RNA viruses and include 141 species classified into four genera according to their phylogenetic relationships: a-, [3-, y-, and 5-coronavirus.
- Coronaviruses are zoonotic viruses that infect a variety of animals from whales to birds, bats, cats, and humans. Typically, CoV infection results in mild to moderate respiratory tract infections; however, some CoV species are extremely virulent and can result in widespread fatality.
- Severe acute respiratory syndrome coronavirus (SARS-CoV) is a human CoV responsible for the first pandemic of the 21 st century, infecting over 8,000 people with a 10% mortality rate.
- Middle East respiratory syndrome coronavirus (MERS-CoV) was identified in November 2012 and had since infected over 1,600 people in 26 countries with a 36% mortality rate. More recently, COVID-19 (SARS CoV2) coronaviruses have raised a global pandemic since first identified in late 2019. Therefore, it is important to identify coronavirus drug targets that can be utilized for the development of broadspectrum anti-coronaviral therapeutics to combat infections of existing and emerging coronaviruses.
- All CoVs express a >800 kDa replicase polyprotein that contains either two or three cysteine proteases, the papain-like protease(s) (PLPpro, nsp3, or PLP1 and PLP2) and the SC- like protease (3CLpro, nsp5, or Mpro). These proteases process the CoV replicase polyprotein by cleaving it into 16 non-structural proteins, which are responsible for a variety of aspects of CoV replication.
- the CoV 3CLpro is responsible for processing 11 cleavage sites of within the replicase polyprotein and is essential for CoV replication, making it a highly valuable target for therapeutic development.
- the overall active site architecture and substrate recognition pockets are structurally conserved across CoV 3CLpros, increasing its attractiveness as a target for the development of broad-spectrum anti-CoV therapeutics.
- high sequence conservation in the vicinity of active site among CoV 3CLpros from different coronavirus subclasses make them an excellent target for the development of broad-spectrum therapeutics for coronavirus infections. Accordingly, the development of CoV 3CLpro inhibitors is a promising path for the treatment of respiratory tract infections and related diseases.
- the disclosure provides, for example, a process for the preparation of compounds which may be inhibitors of proteases, such as the 3C, CL- or 3CL-like protease.
- treating includes any effect, e.g., lessening, reducing, modulating, or eliminating, that results in the improvement of the condition, disease, disorder and the like, including a reduction of viral shedding in asymptomatic individuals and prophylaxis of exposed individuals, independent of symptoms
- alkyl refers to a saturated straight or branched hydrocarbon.
- exemplary alkyl groups include, but are not limited to, straight or branched hydrocarbons of 1-6, 1-4, or 1-3 carbon atoms, referred to herein as Ci-ealkyl, Ci-4alkyl, and Cisalkyl, respectively.
- alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, 2-methyl-l -butyl, 3-methyl-2-butyl, 2-methyl-l -pentyl, 3 -methyl- 1 -pentyl, 4- methyl-1 -pentyl, 2 -methyl -2 -pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-l -butyl, 3, 3 -dimethyl- 1 -butyl, 2 -ethyl- 1 -butyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, etc
- alkenyl refers to an unsaturated straight or branched hydrocarbon having at least one carbon-carbon double bond.
- alkenyl groups include, but are not limited to, a straight or branched group of 2-6 or 3-4 carbon atoms, referred to herein as Ci-Csalkenyl, Cb-Cealkcnyl. and C3-C4alkenyl, respectively.
- alkenyl groups include, but are not limited to, vinyl, allyl, butenyl, pentenyl, etc.
- alkynyl refers to an unsaturated straight or branched hydrocarbon having at least one carbon-carbon triple bond.
- exemplary alkynyl groups include, but are not limited to, straight or branched groups of 2-6, or 3-6 carbon atoms, referred to herein as C2-ealkynyl, and Cvealkynyl. respectively.
- exemplary alkynyl groups include, but are not limited to, ethynyl, propynyl, butynyl, pentynyl, hexynyl, methylpropynyl, etc.
- alkoxy refers to a straight or branched alkyl group attached to oxygen (alkyl-O-).
- alkoxy groups include, but are not limited to, alkoxy groups of 1-6 or 2-6 carbon atoms, referred to herein as Ci-Csalkoxy, Ci-Cealkoxy, and C2- Cealkoxy, respectively.
- alkoxy groups include, but are not limited to methoxy, ethoxy, isopropoxy, etc.
- aryl refers to a radical of a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 electrons shared in a cyclic array) having 6-14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system (“Ce-14 aryl”).
- an aryl group has six ring carbon atoms (“Cearyl”; e.g., phenyl).
- an aryl group has ten ring carbon atoms (“Cio aryl”; e.g., naphthyl such as 1-naphthyl and 2-naphthyl). In some embodiments, an aryl group has fourteen ring carbon atoms (“Ce aryl”; e.g., anthracyl). “Aryl” also includes ring systems wherein the aryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the radical or point of attachment is on the aryl ring, and in such instances, the number of carbon atoms continue to designate the number of carbon atoms in the aryl ring system.
- Typical aryl groups include, but are not limited to, groups derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, as-indacene, s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene, and trinaphthalene.
- Particularly aryl groups include pheny
- R 56 and R 57 may be hydrogen and at least one of R 56 and R 57 is each independently selected from Ci-Cs alkyl, Ci-Cs haloalkyl, 4-10 membered heterocyclyl, alkanoyl, Ci-Cs alkoxy, heteroaryloxy, alkylamino, arylamino, heteroarylamino, NR 58 COR 59 , NR 58 SOR 59 NR 58 SO 2 R 59 , COOalkyl, COOaryl, CONR 58 R 59 , CONR 58 OR 59 , NR 58 R 59 , SO 2 NR 58 R 59 , S-alkyl, SOalkyl, SO 2 alkyl, Saryl, SOaryl, SO 2 aryl; or R 56 and R 57 may be joined to form a cyclic ring (saturated or unsaturated) from 5 to 8 atoms, optionally containing one or more heteroatoms selected from
- R 60 and R 61 are each independently hydrogen, Ci-Cs alkyl, C1-C4 haloalkyl, C3-C10 cycloalkyl, 4-10 membered heterocyclyl, Ce-Cio aryl, substituted Ce-Cio aryl, 5-10 membered heteroaryl, or substituted 5-10 membered heteroaryl.
- carbonyl refers to the radical -C(O)-.
- cyano refers to the radical -CN.
- cycloalkyl or a “carbocyclic group” as used herein refers to a saturated or partially unsaturated hydrocarbon group of, for example, 3-6, or 4-6 carbons, referred to herein as Cs-Ciocycloalkyl, Ci-ecycloalkyl or C4-6Cycloalkyl, respectively.
- exemplary cycloalkyl groups include, but are not limited to, cyclohexyl, cyclopentyl, cyclopentenyl, cyclobutyl or cyclopropyl.
- halo or halogen as used herein refer to F, Cl, Br, or I.
- haloalkyl refers to an alkyl radical in which the alkyl group is substituted with one or more halogens.
- Typical haloalkyl groups include, but are not limited to, trifluoromethyl (i.e. CFs), difluoromethyl, fluoromethyl, chloromethyl, dichloromethyl, dibromoethyl, tribromomethyl, tetrafluoroethyl, and the like.
- Exemplary haloalkyl groups include, but are not limited to, straight or branched hydrocarbons of 1-6, 1-4, or 1-3 carbon atoms substituted with a halogen (i.e. Cl, F, Br and I), referred to herein as Ci- ehaloalkyl, Ci-4 haloalkyl, and Ci-shaloalkyl, respectively.
- hetero when used to describe a compound or a group present on a compound means that one or more carbon atoms in the compound or group have been replaced by a nitrogen, oxygen, or sulfur heteroatom. Hetero may be applied to any of the hydrocarbyl groups described above such as alkyl, e.g., heteroalkyl, cycloalkyl, e.g., heterocyclyl, aryl, e.g,. heteroaryl, cycloalkenyl, e.g. cycloheteroalkenyl, and the like having from 1 to 5, and particularly from 1 to 3 heteroatoms.
- alkyl e.g., heteroalkyl, cycloalkyl, e.g., heterocyclyl, aryl, e.g,. heteroaryl, cycloalkenyl, e.g. cycloheteroalkenyl, and the like having from 1 to 5, and particularly from 1 to 3 heteroatoms.
- heteroaryl or “heteroaromatic group” as used herein refers to an aromatic 5-10 membered ring system containing one or more heteroatoms, for example one to three heteroatoms, such as nitrogen, oxygen, and sulfur.
- the term may also be used to refer to a 5-7 membered monocyclic heteroaryl or an 8-10 membered bicyclic heteroaryl. Where possible, said heteroaryl ring may be linked to the adjacent radical though carbon or nitrogen.
- heteroaryl rings include but are not limited to furan, thiophene, pyrrole, pyrrolopyridine, indole, thiazole, oxazole, isothiazole, isoxazole, imidazole, benzoimidazole, imidazopyridine, pyrazole, triazole, pyridine or pyrimidine, etc.
- each Z is selected from carbonyl, N, NR 65 , O, and S; and R 65 is each independently hydrogen, Ci-Cs alkyl, C3-C10 cycloalkyl, 4-10 membered heterocyclyl, Ce-Cio aryl, or 5-10 membered heteroaryl.
- heterocyclyl refers to saturated or partially unsaturated 4-10 membered ring structures, whose ring structures include one to three heteroatoms, such as nitrogen, oxygen, and sulfur. Where possible, heterocyclyl rings may be linked to the adjacent radical through carbon or nitrogen.
- the term may also be used to refer to 4-10 membered saturated or partially unsaturated ring structures that are bridged, fused or spirocyclic ring structures, whose ring structures include one to three heteroatoms, such as nitrogen, oxygen, and sulfur.
- heterocyclyl groups include, but are not limited to, pyrrolidine, piperidine, morpholine, thiomorpholine, piperazine, oxetane, azetidine, tetrahydrofuran, dihydrofuran, dihydropyran, tetrahydropyran, etc.
- the heterocycle is a spiro heterocycle (e.g., 2,8-diazaspiro[4.5]decane).
- the heterocycle is a bridged heterocycle (e.g., octahydro-lH-4,7- methanoisoindole).
- Spiro heterocyclyl refers to a polycyclic heterocyclyl with rings connected through one common atom (called a spiro atom), wherein the rings have one or more heteroatoms selected from the group consisting of N, O, and S(O) m (wherein m is an integer of 0 to 2) as ring atoms.
- Representative examples of heterocyclyl include, for example:
- hydroxy and “hydroxyl” as used herein refers to the radical -OH.
- “Pharmaceutically or pharmacologically acceptable” include molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, or a human, as appropriate.
- preparations should meet sterility, pyrogenicity, and general safety and purity standards as required by FDA Office of Biologies standards.
- compositions may also contain other active compounds providing supplemental, additional, or enhanced therapeutic functions.
- composition refers to a composition comprising at least one compound as disclosed herein formulated together with one or more pharmaceutically acceptable carriers.
- “Individual,” “patient,” or “subject” are used interchangeably and include any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans.
- the compounds of the disclosure can be administered to a mammal, such as a human, but can also be administered to other mammals such as an animal in need of veterinary treatment, e.g., domestic animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, sheep, pigs, horses, and the like) and laboratory animals (e.g., rats, mice, guinea pigs, and the like).
- “Modulation” includes antagonism (e.g., inhibition), agonism, partial antagonism and/or partial agonism.
- the term “therapeutically effective amount” means the amount of the subject compound that will elicit the biological or medical response of a tissue, system or animal, (e.g. mammal or human) that is being sought by the researcher, veterinarian, medical doctor or other clinician.
- the compounds of the disclosure are administered in therapeutically effective amounts to treat a disease.
- a therapeutically effective amount of a compound is the quantity required to achieve a desired therapeutic and/or prophylactic effect.
- salt(s) refers to salts of acidic or basic groups that may be present in compounds used in the compositions.
- Compounds included in the present compositions that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids.
- the acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, including, but not limited to, malate, oxalate, chloride, bromide, iodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate (i.e., l,l'-m
- Compounds included in the present compositions that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations.
- Examples of such salts include alkali metal or alkaline earth metal salts, particularly calcium, magnesium, sodium, lithium, zinc, potassium, and iron salts.
- Compounds included in the present compositions that include a basic or acidic moiety may also form pharmaceutically acceptable salts with various amino acids.
- the compounds of the disclosure may contain both acidic and basic groups; for example, one amino and one carboxylic acid group. In such a case, the compound can exist as an acid addition salt, a zwitterion, or a base salt.
- the compounds of the disclosure may contain one or more chiral centers and, therefore, exist as stereoisomers.
- stereoisomers when used herein consist of all enantiomers or diastereomers. These compounds may be designated by the symbols “(+),” “R” or “S,” depending on the configuration of substituents around the stereogenic carbon atom, but the skilled artisan will recognize that a structure may denote a chiral center implicitly.
- the present disclosure encompasses various stereoisomers of these compounds and mixtures thereof. Mixtures of enantiomers or diastereomers may be designated “( ⁇ )” in nomenclature, but the skilled artisan will recognize that a structure may denote a chiral center implicitly.
- the compounds of the disclosure may contain one or more double bonds and, therefore, exist as geometric isomers resulting from the arrangement of substituents around a carbon-carbon double bond.
- the symbol — denotes a bond that may be a single, double or triple bond as described herein.
- Substituents around a carbon-carbon double bond are designated as being in the “Z” or “E” configuration wherein the terms “Z” and “E” are used in accordance with IUPAC standards. Unless otherwise specified, structures depicting double bonds encompass both the “E” and “Z” isomers.
- Substituents around a carbon-carbon double bond alternatively can be referred to as “cis” or “trans,” where “cis” represents substituents on the same side of the double bond and “trans” represents substituents on opposite sides of the double bond.
- Compounds of the disclosure may contain a carbocyclic or heterocyclic ring and therefore, exist as geometric isomers resulting from the arrangement of substituents around the ring.
- the arrangement of substituents around a carbocyclic or heterocyclic ring are designated as being in the “Z” or “E” configuration wherein the terms “Z” and “E” are used in accordance with IUPAC standards.
- structures depicting carbocyclic or heterocyclic rings encompass both “Z” and “E” isomers.
- Substituents around a carbocyclic or heterocyclic rings may also be referred to as “cis” or “trans”, where the term “cis” represents substituents on the same side of the plane of the ring and the term “trans” represents substituents on opposite sides of the plane of the ring. Mixtures of compounds wherein the substituents are disposed on both the same and opposite sides of plane of the ring are designated “cis/trans.”
- Stereoselective syntheses a chemical or enzymatic reaction in which a single reactant forms an unequal mixture of stereoisomers during the creation of a new stereocenter or during the transformation of a pre-existing one, are well known in the art.
- Stereoselective syntheses encompass both enantio- and diastereoselective transformations, and may involve the use of chiral auxiliaries. For examples, see Carreira and Kvaemo, Classics in Stereoselective Synthesis, Wiley-VCH: Weinheim, 2009.
- the compounds disclosed herein can exist in solvated as well as unsolvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the disclosure embrace both solvated and unsolvated forms.
- the compound is amorphous.
- the compound is a single polymorph.
- the compound is a mixture of polymorphs.
- the compound is in a crystalline form.
- the disclosure also embraces isotopically labeled compounds of the disclosure which are identical to those recited herein, except that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
- isotopes that can be incorporated into compounds of the disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine, such as 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 17 0, 31 P, 32 P, 35 S, 18 F, and 36 C1, respectively.
- a compound of the disclosure may have one or more H atom replaced with deuterium.
- isotopically-labeled disclosed compounds are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., 3 H) and carbon- 14 (i.e., 14 C) isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., 2 H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances.
- Isotopically labeled compounds of the disclosure can generally be prepared by following procedures analogous to those disclosed in the examples herein by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.
- prodrug refers to compounds that are transformed in vivo to yield a disclosed compound or a pharmaceutically acceptable salt, hydrate or solvate of the compound. The transformation may occur by various mechanisms (such as by esterase, amidase, phosphatase, oxidative and or reductive metabolism) in various locations (such as in the intestinal lumen or upon transit of the intestine, blood or liver). Prodrugs are well known in the art (for example, see Rautio, Kumpulainen, et al, Nature Reviews Drug Discovery 2008, 7, 255).
- a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a group such as (Ci-x)alkyl.
- a prodrug can be formed by the replacement of the hydrogen atom of the alcohol group with a group such as (Ci-6)alkylcarbonyloxymethyl, l-((Ci-6)alkylcarbonyloxy)ethyl, l-methyl-l-((Ci- 6)alkylcarbonyloxy)ethyl (Ci-6)alkoxycarbonyloxymethyl, N-(Ci-6)alkoxycarbonylaminomethyl, succinoyl, (Ci-e)alkylcarbonyl, a-amino(Ci-4)alkylcarbonyl, arylalkylcarbonyl and a- aminoalkylcarbonyl, or a-aminoalkylcarbonyl-a-aminoalkylcarbonyl, where each > - aminoalkylcarbonyl group is independently selected from the naturally occurring L-amino acids, P(O)(
- a prodrug can be formed, for example, by creation of an amide or carbamate, an N-alkylcarbonyloxyalkyl derivative, an (oxodioxolenyl)methyl derivative, an N-Mannich base, imine or enamine.
- a secondary amine can be metabolically cleaved to generate a bioactive primary amine, or a tertiary amine can metabolically cleaved to generate a bioactive primary or secondary amine.
- warhead refers to a functional group present on a compound wherein that functional group is capable of reversibly or irreversibly participating in a reaction with a protein, e.g., 3C or 3CL protease (e.g., with a cysteine on the protease such as Cys 145).
- Warheads may, for example, form covalent bonds with the protein, or may create stable transition states, or be a reversible or an irreversible alkylating agent.
- the warhead moiety can be a functional group on an inhibitor that can participate in a bond-forming reaction, wherein a new covalent bond is formed between a portion of the warhead and a donor, for example an amino acid residue of a protein.
- the warhead is an electrophile and the “donor” is a nucleophile such as the side chain of a cysteine residue.
- a warhead may include a nitrile group.
- nitriles may be reversible covalent warheads for cysteine protease inhibition.
- the mechanism of action may involve a formation of reversible covalent bond between the nitrile and the active cysteine to form a thioimidate adduct.
- Reaction of cysteine of glutathione or other proteins is generally reversible, while the reaction with cysteine or aminoethylthiols generally irreversibly forms a thiazolidine adduct.
- contemplated compounds herein may be a reversible or an irreversible inhibitor.
- inhibitor refers to a compound that binds to and /or inhibits a target protease with measurable affinity.
- reversible or "reversible inhibitor” as used herein refers to a protease inhibitor that associates with a protease in such a way as to inhibit the activity of the protease while the protease and inhibitor are bound, but does not associate with a protease in such a way as to inhibit the activity of the protease when the protease and inhibitor are no longer bound.
- Reversible inhibitors can affect inhibition by competing with substrate for binding to the active site of the protease (competitive reversible inhibitor), or by associating with the protease bound to its substrate in a way to make the complex inactive (uncompetitive reversible inhibitor), or by associating with the protease and/or protease-substrate complex in a way that inhibits the activity of either and/or both.
- the term “irreversible” or “irreversible inhibitor” refers to an inhibitor (i.e., a compound) that can be covalently bonded to a target protease in a substantially non-reversible manner.
- An irreversible inhibitor will remain substantially bound to the target protease once covalent bond formation has occurred.
- Irreversible inhibitors usually display time dependency, whereby the degree of inhibition increases with the time with which the inhibitor is in contact with the enzyme.
- an irreversible inhibitor will remain substantially bound to target protease once covalent bond formation has occurred and will remain bound for a time period that is longer than the life of the protein.
- purity means one or more of the following: chiral purity, enantiomeric purity/enantiomerically pure, free of impurities (e.g., primary amide impurities, epimer impurities, and isomer impurities), substantially pure, and purity of any intermediates in the process of preparing a compound (for example, a compound of Formula I).
- impurities e.g., primary amide impurities, epimer impurities, and isomer impurities
- a process for the preparation of a compound of Formula I: Formula I comprising: providing a compound of Formula VI: Formula VI; coupling the compound of Formula VI with a compound of Formula VII, or a salt thereof:
- Formula VIII Formula VIII; amidating the compound of Formula VIII to produce a compound of Formula IX: Formula IX; and dehydrating the compound of Formula IX to provide the compound of Formula I; wherein R 1 is selected from the group consisting of H, halogen, Ci-ealkyl, and Ci-ealkoxy; R 2a , R 2b , R 2c , and R 2d are independently, for each occurrence, selected from the group consisting of H, halogen, Ci- ealkyl, and Ci-ealkoxy; R 3 is selected from the group consisting of methyl, ethyl, propyl, and butyl; R l is independently, for each occurrence, H or Ci-ealkyl; or two R l may be taken, together with the carbon to which they are attached, to form a Cs-C locycloalkyl; and n is 0 or 1.
- R 1 is selected from the group consisting of H, halogen, Ci-ealkyl, and Ci-ealkoxy
- R 2a , R 2b , R 2C , and R 2d are independently, for each occurrence, selected from the group consisting of H, halogen, Ci-ealkyl, and Ci-ealkoxy
- R 3 is selected from the group consisting of methyl, ethyl, propyl, and butyl
- R l is independently, for each occurrence, H or Ci-ealkyl; or two R l may be taken, together with the carbon to which they are attached, to form a Cs-Ciocycloalkyl
- n is 0 or 1.
- R 1 is H.
- R 2a , R 2b , and R 2c are H.
- R 2d is halogen.
- R 2a , R 2b , and R 2c are H; and R 2d is chloro.
- R 3 is methyl
- R l is H.
- R l is methyl. In some embodiments, R l selected from the group consisting of methyl, ethyl, propyl, and butyl.
- two R l are taken, together with the carbon to which they are attached, to form a cyclopropyl, cyclobutyl, or oxetanyl.
- n is 1. In various embodiments, n is 0.
- providing the compound of Formula VI comprises: providing a compound of Formula IV : Formula IV; and activating the compound of Formula IV to provide the compound of Formula VI; wherein LG is a leaving group.
- the compound of Formula VI is prepared by activating the compound of Formula IV to provide the compound of Formula VI; wherein LG is a leaving group.
- LG is halogen
- LG is selected from the group consisting of fluoro, chloro, bromo, and pentafluorophenolate.
- LG is chloro
- providing the compound of Formula VI comprises: halogenating a compound of Formula III: Formula III; to produce a compound of Formula IV : Formula IV, wherein LG is a halogen; and amidating the compound of Formula IV to provide the compound of Formula VI.
- the compound of Formula VI is prepared by halogenating a compound of Formula III: Formula III; to produce a compound of Formula IV : Formula IV, wherein LG is a halogen; and amidating the compound of Formula IV to provide the compound of Formula VI.
- LG is selected from the group consisting of fluoro, bromo, and chloro.
- coupling the compound of Formula VI with the compound of Formula VII, or a salt thereof comprises contacting the compound of Formula VI with the compound of Formula VII, or a salt thereof, in the presence of a coupling reagent.
- the coupling reagent is 2-(lH-Benzotriazole-l-yl)-l, 1,3,3- tetramethylaminium tetrafluoroborate (TBTU).
- coupling the compound of Formula VI with the compound of Formula VII, or a salt thereof further comprises a base.
- the salt of the compound of Formula VII is:
- the salt of the compound of Formula VII is: [00073]
- the base is N,N-diisopropylethylamine (DIPEA).
- amidating the compound of Formula VIII comprises contacting the compound of Formula VIII with NHs. In some embodiments, amidating the compound of Formula VIII comprises contacting the compound of Formula VIII with NHs and 1 ,8-diazabicyclo(5.4.0)undec-7 -ene (DBU) .
- DBU 1,8-diazabicyclo(5.4.0)undec-7 -ene
- dehydrating the compound of Formula IX comprises contacting the compound of Formula IX with a trifluoroacetic acid anhydride; a propanephosphonic acid anhydride; or a propanephosphonic acid anhydride and N- methylmorpholine .
- dehydrating the compound of Formula IX comprises contacting the compound of Formula IX with a trifluoroacetic acid anhydride.
- dehydrating the compound of Formula IX comprises contacting the compound of Formula IX with a propanephosphonic acid anhydride. In some embodiments, dehydrating the compound of Formula IX comprises contacting the compound of Formula IX with A'-mc thy 1 morpholine. In some embodiments, dehydrating the compound of Formula IX comprises contacting the compound of Formula IX with a propanephosphonic acid anhydride and A'-mcthyl morpholine.
- halogenating the carboxylic acid represented by Formula III comprises contacting the compound of Formula III with (COC1)2 in the presence of a solvent and a co-solvent.
- the solvent is dichloromethane. In embodiments, the solvent is tertbutyl methyl ether. In embodiments, the solvent is a mixture of dichloromethane and tert-butyl methyl ether.
- the co-solvent is dimethylformamide.
- amidating the compound of Formula IV comprises contacting the compound of Formula IV with (S)-2-amino-3-cyclopropylpropanoic acid in the presence of a base.
- the base is Na2COs.
- providing the compound of Formula III comprises: forming a salt of a compound of Formula III: Formula III; isolating the salt of the compound of Formula III; and contacting the salt of the compound of Formula III with an acid to produce a pure compound of Formula III.
- the compound of Formula III is prepared by isolating the salt of the compound of Formula III; and contacting the salt of the compound of Formula III with an acid to produce a pure compound of Formula III.
- forming the salt of the compound of Formula III comprises contacting the compound of Formula III with dicyclohexylamine.
- the acid is phosphoric acid.
- the compound of Formula I is provided in greater than about
- the purity is chiral purity.
- the compound of Formula I is: the compound of Formula VI is: the compound of Formula VII, or salt thereof, is: the compound of Formula VIII is: the compound of Formula IX is:
- the compound of Formula I is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoe [00090] in various embodiments, N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- the compound of Formula I is provided in greater than about 99% purity.
- the purity is chiral purity.
- the compound of Formula IV is:
- the compound of Formula III is:
- the compound of Formula I is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoe-N-[00097]
- the compound has 98% or 99% purity. In some embodiments, the compound has 98%. In some embodiments, the compound has 99%.
- the compound has greater than 95% purity (e.g., greater than 96%, 97%, 98%, or 99% purity).
- the purity is chiral purity.
- an impurity is removed from the compound of any one of Formula I, Formula II, Formula III, Formula IV, Formula VI, Formula VII or salt thereof, Formula VIII, and Formula IX is purified prior to using the compound in any of the processes described herein.
- water is removed from the compound of any one of Formula I, Formula II, Formula III, Formula IV, Formula VI, Formula VII or salt thereof, Formula VIII, and Formula IX is purified prior to using the compound in any of the processes described herein.
- the compound of any one of Formula I, Formula II, Formula III, Formula IV, Formula VI, Formula VII or salt thereof, Formula VIII, and Formula IX is dried prior to using the compound in any of the processes described herein.
- the compound of any one of Formula I, Formula II, Formula III, Formula IV, Formula VI, Formula VII or salt thereof, Formula VIII, and Formula IX is purified prior to using the compound in any of the processes described herein.
- purification comprises distillation, precipitation, crystallization, extraction, chromatography, or any combination thereof.
- Example 1 A Process Description for the Preparation of 7-chloro-N-((S)-l-(((S)-l-cyano-2- ((S)-2-oxopiperidin-3-yl)ethyl)amino)-3-cyclopropyl-l-oxopropan-2-yl)-lH-indole-2- carboxamide
- Chloro- lH-indole-2 -carboxylic acid (10.0 kg) and dichloromethane (200 L) were charged into a reactor under N2 atmosphere at about 10-20 °C. Then, dimethylformamide (299g, 0.08 eq) was charged into the reactor under N2 at about 10-20 °C. (COC1)2 (13.0 kg, 2.00 eq) was charged into the reaction mixture drop-wise at about 5-10 °C in about 2-3 hours. After the addition, the mixture was stirred at about 10-20 °C for about another 6 hours. The mixture was filtered and the filter cake was rinsed with dichloromethane (20.0 L).
- the internal temperature of the reactor was kept at about 0-5 °C, and then a solution of 7- chloro- lH-indole-2 -carbonyl chloride (11.0 kg) in dichloromethane (88.0 L) was added dropwise into the reaction mixture over 3 hours. After the addition, the reaction mixture was stirred at about 0-5 °C for 1 hour. The reaction mixture was warmed to about 10-20 °C, and then water (22.0 L) was charged into the reaction mixture. The resulting mixture was stirred at about 10- 20 °C for 30 minutes, and then the mixture was settled for additional 30 minutes, thereby forming two layers.
- Extraction was performed by charging tetrahydrofuran (110 L) to the aqueous layer and charging HC1 (aq.) (3 mol/L) to adjust the pH to about 1 at a temperature of about 10-20 °C, and then the reaction mixture was stirred for 30 minutes. The resulting two layers were separated. The organic layer was concentrated to about 33.0 L, and the residue was charged to another reactor and heated to a temperature of about 70-80 °C. n-Heptane (66.0 L) was charged drop-wise into the reactor at about 70-80 °C, and then the reaction mixture was stirred at about 70-80 °C for 4 hours.
- the reaction mixture was cooled to 10-20 °C slowly over 8 hours, and then the mixture was stirred at about 10-20 °C for additional 12 hours.
- the filtrate cake was obtained after filtration of the reaction mixture, and then the filter cake was rinsed with water (110 L).
- the filter cake was dried under vacuum to obtain A)-2-(7-chloro- 1 H-indolc-2- carboxamido)-3 -cyclopropylpropanoic acid (13.0 kg).
- Example 2 A Large-Scale Synthesis of 7-chloro-N-((S)-l-(((S)-l-cyano-2-((S)-2- oxopiperidin-3-yl)ethyl)amino)-3-cyclopropyl-l-oxopropan-2-yl)-lH-indole-2-carboxamide
- Example 3 A Large-Scale Synthesis of 7-chloro-N-((S)-l-(((S)-l-cyano-2-((S)-2- oxopiperidin-3-yl)ethyl)amino)-3-cyclopropyl-l-oxopropan-2-yl)-lH-indole-2-carboxamide
- Example 4 A Large-Scale Synthesis of 7-chloro-N-((S)-l-(((S)-l-cyano-2-((S)-2- oxopiperidin-3-yl)ethyl)amino)-3-cyclopropyl-l-oxopropan-2-yl)-lH-indole-2-carboxamide
- MTBE tert-butyl methyl ether
- the crude product was then charged with MTBE (5 L/kg) and silica gel (230-400) (1.5 kg/kg) was added and stirred for 1 hour at 25 °C.
- the mixture was fdtered through celite bed. Celite bed washed with MTBE (3 L/kg).
- a first reaction vessel was then charged with Raney Nickel (0.7 kg/kg) under inert atmosphere.
- a second reaction vessel was charged with methanol (8 L/kg) and dimethyl (2S,4S)-2-((tert-butoxycarbonyl)amino)-4-(2-cyanoethyl)pentanedioate (1.0 kg/kg), which was then passed through CUNO filter and washed with methanol (2 L/kg).
- This solution was then added to the first reaction vessel.
- triethylamine (TEA) (0.46 kg/kg) was added to the reaction mixture.
- the reaction mixture was then degassed with argon, followed by hydrogen. Hydrogen pressure was applied at 70-73 psi with stirring at 25 °C. Then the reaction mixture was heated to 50 °C for at least 16 hours, maitaining 70-73 psi of hydrogen pressure.
- reaction mixture from the first vessel was added to the second vessel at 15 °C dropwise.
- the resulting reaction mixture was stirred for 2 hours at 15 °C.
- reaction mixture was then cooled to 15 °C, and 3N HC1 (6-9X) was added to adjust the pH to 1.
- the reaction mixture was then stirred for 1 h at 15 °C. After letting stand for 30 minutes, the lower aqueous layer was discharged, and the organic layer was filtered through CUNO filter. Product was isolated by washing with ⁇ -heptane. The product was mixed with water, heated, and stirred. Product was isolated by filtration, washed with water and dried in the oven in vacuo.
- JV-methylmorpholine (NMM) (96.1 g/104.4 mb, 5.0 equiv.) to the vessel at 28-32 °C over a minimum of 15 minutes followed by a line rinse of ethyl acetate (90 mb, 1.0 part). Heated the reaction mixture to 48-53 °C, target 50 °C.
- propanephosphonic acid anhydride (TsP) as a 50% wt solution in EtOAc (423.2 g/395.5 mL, 3.5 equiv.) at 50-55 °C over 20 to 30 minutes followed by a line rinse of ethyl acetate (90 mb, 1.0 part) to the vessel at 50-55 °C. Stirred the reaction for 1.5 to 2 hours at 50-55 °C, target 53 °C.
- articles such as “a,” “an,” and “the” may mean one or more than one unless indicated to the contrary or otherwise evident from the context. Claims or descriptions that include “or” between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context.
- the invention includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process.
- the invention includes embodiments in which more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process.
- the invention encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, and descriptive terms from one or more of the listed claims is introduced into another claim.
- any claim that is dependent on another claim can be modified to include one or more limitations found in any other claim that is dependent on the same base claim.
- elements are presented as lists, e.g., in Markush group format, each subgroup of the elements is also disclosed, and any element(s) can be removed from the group. It should it be understood that, in general, where the invention, or aspects of the invention, is/are referred to as comprising particular elements and/or features, certain embodiments of the invention or aspects of the invention consist, or consist essentially of, such elements and/or features.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The disclosure provides a process for the preparation of compounds with nitrile warheads, e.g., a compound of Formula I, contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease.
Description
PROCESS FOR MAKING CYSTEINE PROTEASE INHIBITORS AND COMPOUNDS PROVIDED BY THAT PROCESS
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The application claims the benefit of, and priority to, U.S.S.N. 63/246,118, filed September 20, 2021; the contents of which is incorporated herein by reference.
BACKGROUND
[0002] The Coronaviridae family of viruses are enveloped, single-stranded, positive-sense RNA viruses and include 141 species classified into four genera according to their phylogenetic relationships: a-, [3-, y-, and 5-coronavirus. Coronaviruses (CoVs) are zoonotic viruses that infect a variety of animals from whales to birds, bats, cats, and humans. Typically, CoV infection results in mild to moderate respiratory tract infections; however, some CoV species are extremely virulent and can result in widespread fatality. Severe acute respiratory syndrome coronavirus (SARS-CoV) is a human CoV responsible for the first pandemic of the 21st century, infecting over 8,000 people with a 10% mortality rate. Middle East respiratory syndrome coronavirus (MERS-CoV) was identified in November 2012 and had since infected over 1,600 people in 26 countries with a 36% mortality rate. More recently, COVID-19 (SARS CoV2) coronaviruses have raised a global pandemic since first identified in late 2019. Therefore, it is important to identify coronavirus drug targets that can be utilized for the development of broadspectrum anti-coronaviral therapeutics to combat infections of existing and emerging coronaviruses.
[0003] All CoVs express a >800 kDa replicase polyprotein that contains either two or three cysteine proteases, the papain-like protease(s) (PLPpro, nsp3, or PLP1 and PLP2) and the SC- like protease (3CLpro, nsp5, or Mpro). These proteases process the CoV replicase polyprotein by cleaving it into 16 non-structural proteins, which are responsible for a variety of aspects of CoV replication. The CoV 3CLpro is responsible for processing 11 cleavage sites of within the replicase polyprotein and is essential for CoV replication, making it a highly valuable target for therapeutic development. The overall active site architecture and substrate recognition pockets are structurally conserved across CoV 3CLpros, increasing its attractiveness as a target for the development of broad-spectrum anti-CoV therapeutics. Moreover, high sequence conservation in the vicinity of active site among CoV 3CLpros from different coronavirus subclasses make
them an excellent target for the development of broad-spectrum therapeutics for coronavirus infections. Accordingly, the development of CoV 3CLpro inhibitors is a promising path for the treatment of respiratory tract infections and related diseases.
[0004] Numerous studies on targeting the immediate zoonotic reservoirs of coronaviruses with small molecule inhibitors have helped inform structure -based design strategies aimed at creating molecular scaffolds that may aid in the development of therapeutic against coronaviral infection; however, small molecule antiviral agents or effective commercially available broadspectrum therapeutics have not yet been identified. There is a critical need for the development of broad-spectrum CoV therapeutics to overcome the challenges of traditional anti-CoV therapeutic development, as broad-spectrum therapeutics can be rapidly implemented upon zoonotic disease outbreak.
SUMMARY
[0005] The disclosure provides, for example, a process for the preparation of compounds which may be inhibitors of proteases, such as the 3C, CL- or 3CL-like protease.
[0006] In certain embodiments, provided herein is a process for the preparation of a compound of Formula I:
Formula I.
DETAILED DESCRIPTION
[0007] The features and other details of the disclosure will now be more particularly described. Before further description of the present disclosure, certain terms employed in the specification, examples and appended claims are collected here. These definitions should be read in light of the remainder of the disclosure and as understood by a person of skill in the art. Unless defined otherwise, all technical and scientific terms used herein have the same meaning
as commonly understood by a person of ordinary skill in the art.
Definitions
[0008] The term “treating” includes any effect, e.g., lessening, reducing, modulating, or eliminating, that results in the improvement of the condition, disease, disorder and the like, including a reduction of viral shedding in asymptomatic individuals and prophylaxis of exposed individuals, independent of symptoms
[0009] The term “alkyl” as used herein refers to a saturated straight or branched hydrocarbon. Exemplary alkyl groups include, but are not limited to, straight or branched hydrocarbons of 1-6, 1-4, or 1-3 carbon atoms, referred to herein as Ci-ealkyl, Ci-4alkyl, and Cisalkyl, respectively. Exemplary alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, 2-methyl-l -butyl, 3-methyl-2-butyl, 2-methyl-l -pentyl, 3 -methyl- 1 -pentyl, 4- methyl-1 -pentyl, 2 -methyl -2 -pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-l -butyl, 3, 3 -dimethyl- 1 -butyl, 2 -ethyl- 1 -butyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, etc
[00010] The term “alkenyl” as used herein refers to an unsaturated straight or branched hydrocarbon having at least one carbon-carbon double bond. Exemplary alkenyl groups include, but are not limited to, a straight or branched group of 2-6 or 3-4 carbon atoms, referred to herein as Ci-Csalkenyl, Cb-Cealkcnyl. and C3-C4alkenyl, respectively. Exemplary alkenyl groups include, but are not limited to, vinyl, allyl, butenyl, pentenyl, etc.
[00011] The term “alkynyl” as used herein refers to an unsaturated straight or branched hydrocarbon having at least one carbon-carbon triple bond. Exemplary alkynyl groups include, but are not limited to, straight or branched groups of 2-6, or 3-6 carbon atoms, referred to herein as C2-ealkynyl, and Cvealkynyl. respectively. Exemplary alkynyl groups include, but are not limited to, ethynyl, propynyl, butynyl, pentynyl, hexynyl, methylpropynyl, etc.
[00012] The term “alkoxy” as used herein refers to a straight or branched alkyl group attached to oxygen (alkyl-O-). Exemplary alkoxy groups include, but are not limited to, alkoxy groups of 1-6 or 2-6 carbon atoms, referred to herein as Ci-Csalkoxy, Ci-Cealkoxy, and C2- Cealkoxy, respectively. Exemplary alkoxy groups include, but are not limited to methoxy, ethoxy, isopropoxy, etc.
[00013] The term “aryl” refers to a radical of a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 electrons shared in a cyclic array) having 6-14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system (“Ce-14 aryl”). In some embodiments, an aryl group has six ring carbon atoms (“Cearyl”; e.g., phenyl). In some embodiments, an aryl group has ten ring carbon atoms (“Cio aryl”; e.g., naphthyl such as 1-naphthyl and 2-naphthyl). In some embodiments, an aryl group has fourteen ring carbon atoms (“Ce aryl”; e.g., anthracyl). “Aryl” also includes ring systems wherein the aryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the radical or point of attachment is on the aryl ring, and in such instances, the number of carbon atoms continue to designate the number of carbon atoms in the aryl ring system. Typical aryl groups include, but are not limited to, groups derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, as-indacene, s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene, and trinaphthalene. Particularly aryl groups include phenyl, naphthyl, indenyl, and tetrahydronaphthyl. Examples of representative substituted aryls include the following
[00015] wherein one of R56 and R57 may be hydrogen and at least one of R56 and R57 is each independently selected from Ci-Cs alkyl, Ci-Cs haloalkyl, 4-10 membered heterocyclyl, alkanoyl, Ci-Cs alkoxy, heteroaryloxy, alkylamino, arylamino, heteroarylamino, NR58COR59, NR58SOR59NR58SO2R59, COOalkyl, COOaryl, CONR58R59, CONR58OR59, NR58R59, SO2NR58R59, S-alkyl, SOalkyl, SO2alkyl, Saryl, SOaryl, SO2aryl; or R56 and R57 may be joined to form a cyclic ring (saturated or unsaturated) from 5 to 8 atoms, optionally containing one or more heteroatoms selected from the group N, O, or S. R60 and R61 are each independently hydrogen, Ci-Cs alkyl, C1-C4 haloalkyl, C3-C10 cycloalkyl, 4-10 membered heterocyclyl, Ce-Cio aryl, substituted Ce-Cio aryl, 5-10 membered heteroaryl, or substituted 5-10 membered heteroaryl.
[00016] The term “carbonyl” as used herein refers to the radical -C(O)-.
[00017] The term “cyano” as used herein refers to the radical -CN.
[00018] The terms “cycloalkyl” or a “carbocyclic group” as used herein refers to a saturated or partially unsaturated hydrocarbon group of, for example, 3-6, or 4-6 carbons, referred to herein as Cs-Ciocycloalkyl, Ci-ecycloalkyl or C4-6Cycloalkyl, respectively. Exemplary cycloalkyl groups include, but are not limited to, cyclohexyl, cyclopentyl, cyclopentenyl, cyclobutyl or cyclopropyl.
[00019] The terms “halo” or “halogen” as used herein refer to F, Cl, Br, or I.
[00020] The terms “haloalkyl” as used herein refers to an alkyl radical in which the alkyl group is substituted with one or more halogens. Typical haloalkyl groups include, but are not limited to, trifluoromethyl (i.e. CFs), difluoromethyl, fluoromethyl, chloromethyl, dichloromethyl, dibromoethyl, tribromomethyl, tetrafluoroethyl, and the like. Exemplary haloalkyl groups include, but are not limited to, straight or branched hydrocarbons of 1-6, 1-4, or 1-3 carbon atoms substituted with a halogen (i.e. Cl, F, Br and I), referred to herein as Ci- ehaloalkyl, Ci-4 haloalkyl, and Ci-shaloalkyl, respectively.
[00021] The term “hetero” when used to describe a compound or a group present on a compound means that one or more carbon atoms in the compound or group have been replaced by a nitrogen, oxygen, or sulfur heteroatom. Hetero may be applied to any of the hydrocarbyl groups described above such as alkyl, e.g., heteroalkyl, cycloalkyl, e.g., heterocyclyl, aryl, e.g,. heteroaryl, cycloalkenyl, e.g. cycloheteroalkenyl, and the like having from 1 to 5, and particularly from 1 to 3 heteroatoms.
[00022] The terms “heteroaryl” or “heteroaromatic group” as used herein refers to an aromatic 5-10 membered ring system containing one or more heteroatoms, for example one to three heteroatoms, such as nitrogen, oxygen, and sulfur. The term may also be used to refer to a 5-7 membered monocyclic heteroaryl or an 8-10 membered bicyclic heteroaryl. Where possible, said heteroaryl ring may be linked to the adjacent radical though carbon or nitrogen. Examples of heteroaryl rings include but are not limited to furan, thiophene, pyrrole, pyrrolopyridine, indole, thiazole, oxazole, isothiazole, isoxazole, imidazole, benzoimidazole, imidazopyridine, pyrazole, triazole, pyridine or pyrimidine, etc.
[00023] Examples of representative heteroaryls include the following:
[00024] wherein each Z is selected from carbonyl, N, NR65, O, and S; and R65 is each independently hydrogen, Ci-Cs alkyl, C3-C10 cycloalkyl, 4-10 membered heterocyclyl, Ce-Cio aryl, or 5-10 membered heteroaryl.
[00025] The terms “heterocyclyl,” “heterocycle,” or “heterocyclic group” are art-recognized and refer to saturated or partially unsaturated 4-10 membered ring structures, whose ring structures include one to three heteroatoms, such as nitrogen, oxygen, and sulfur. Where possible, heterocyclyl rings may be linked to the adjacent radical through carbon or nitrogen. The term may also be used to refer to 4-10 membered saturated or partially unsaturated ring structures that are bridged, fused or spirocyclic ring structures, whose ring structures include one to three heteroatoms, such as nitrogen, oxygen, and sulfur. Examples of heterocyclyl groups include, but are not limited to, pyrrolidine, piperidine, morpholine, thiomorpholine, piperazine, oxetane, azetidine, tetrahydrofuran, dihydrofuran, dihydropyran, tetrahydropyran, etc. In some embodiments, the heterocycle is a spiro heterocycle (e.g., 2,8-diazaspiro[4.5]decane). In some embodiments, the heterocycle is a bridged heterocycle (e.g., octahydro-lH-4,7- methanoisoindole). "Spiro heterocyclyl," or “spiro heterocycle” refers to a polycyclic heterocyclyl with rings connected through one common atom (called a spiro atom), wherein the rings have one or more heteroatoms selected from the group consisting of N, O, and S(O)m (wherein m is an integer of 0 to 2) as ring atoms. Representative examples of heterocyclyl include, for example:
[00026] The terms “hydroxy” and “hydroxyl” as used herein refers to the radical -OH.
[00027] The term “oxo” as used herein refers to the radical =0.
[00028] “Pharmaceutically or pharmacologically acceptable” include molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, or a human, as appropriate. For human administration, preparations should meet sterility, pyrogenicity, and general safety and purity standards as required by FDA Office of Biologies standards.
[00029] The term “pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” as used herein refers to any and all solvents, dispersion media, coatings, isotonic and absorption delaying agents, and the like, that are compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. The compositions may also contain other active compounds providing supplemental, additional, or enhanced therapeutic functions.
[00030] The term “pharmaceutical composition” as used herein refers to a composition comprising at least one compound as disclosed herein formulated together with one or more pharmaceutically acceptable carriers.
[00031] ‘Individual,” “patient,” or “subject” are used interchangeably and include any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans. The compounds of the disclosure can be administered to a mammal, such as a human, but can also be administered to other mammals such as an animal in need of veterinary treatment, e.g., domestic animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, sheep, pigs, horses, and the like) and laboratory animals (e.g., rats, mice, guinea pigs, and the like). “Modulation” includes antagonism (e.g., inhibition), agonism, partial antagonism and/or partial agonism.
[00032] In the present specification, the term “therapeutically effective amount” means the amount of the subject compound that will elicit the biological or medical response of a tissue,
system or animal, (e.g. mammal or human) that is being sought by the researcher, veterinarian, medical doctor or other clinician. The compounds of the disclosure are administered in therapeutically effective amounts to treat a disease. Alternatively, a therapeutically effective amount of a compound is the quantity required to achieve a desired therapeutic and/or prophylactic effect.
[00033] The term "pharmaceutically acceptable salt(s)" as used herein refers to salts of acidic or basic groups that may be present in compounds used in the compositions. Compounds included in the present compositions that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. The acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, including, but not limited to, malate, oxalate, chloride, bromide, iodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate (i.e., l,l'-methylene-bis-(2-hydroxy-3- naphthoate)) salts. Compounds included in the present compositions that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include alkali metal or alkaline earth metal salts, particularly calcium, magnesium, sodium, lithium, zinc, potassium, and iron salts. Compounds included in the present compositions that include a basic or acidic moiety may also form pharmaceutically acceptable salts with various amino acids. The compounds of the disclosure may contain both acidic and basic groups; for example, one amino and one carboxylic acid group. In such a case, the compound can exist as an acid addition salt, a zwitterion, or a base salt.
[00034] The compounds of the disclosure may contain one or more chiral centers and, therefore, exist as stereoisomers. The term “stereoisomers” when used herein consist of all enantiomers or diastereomers. These compounds may be designated by the symbols “(+),”
“R” or “S,” depending on the configuration of substituents around the stereogenic carbon atom, but the skilled artisan will recognize that a structure may denote a chiral center implicitly. The present disclosure encompasses various stereoisomers of these compounds and mixtures thereof. Mixtures of enantiomers or diastereomers may be designated “(±)” in nomenclature, but the skilled artisan will recognize that a structure may denote a chiral center implicitly.
[00035] The compounds of the disclosure may contain one or more double bonds and, therefore, exist as geometric isomers resulting from the arrangement of substituents around a carbon-carbon double bond. The symbol — denotes a bond that may be a single, double or triple bond as described herein. Substituents around a carbon-carbon double bond are designated as being in the “Z” or “E” configuration wherein the terms “Z” and “E” are used in accordance with IUPAC standards. Unless otherwise specified, structures depicting double bonds encompass both the “E” and “Z” isomers. Substituents around a carbon-carbon double bond alternatively can be referred to as “cis” or “trans,” where “cis” represents substituents on the same side of the double bond and “trans” represents substituents on opposite sides of the double bond.
[00036] Compounds of the disclosure may contain a carbocyclic or heterocyclic ring and therefore, exist as geometric isomers resulting from the arrangement of substituents around the ring. The arrangement of substituents around a carbocyclic or heterocyclic ring are designated as being in the “Z” or “E” configuration wherein the terms “Z” and “E” are used in accordance with IUPAC standards. Unless otherwise specified, structures depicting carbocyclic or heterocyclic rings encompass both “Z” and “E” isomers. Substituents around a carbocyclic or heterocyclic rings may also be referred to as “cis” or “trans”, where the term “cis” represents substituents on the same side of the plane of the ring and the term “trans” represents substituents on opposite sides of the plane of the ring. Mixtures of compounds wherein the substituents are disposed on both the same and opposite sides of plane of the ring are designated “cis/trans.”
[00037] Individual enantiomers and diastereomers of compounds of the present disclosure can be prepared synthetically from commercially available starting materials that contain asymmetric or stereogenic centers, or by preparation of racemic mixtures followed by resolution methods well known to those of ordinary skill in the art. These methods of resolution are exemplified by (1) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and liberation of the optically pure product from the auxiliary, (2) salt formation employing an optically active resolving agent, (3) direct separation of the mixture of optical enantiomers on chiral liquid chromatographic columns or (4) kinetic resolution using stereoselective chemical or enzymatic reagents. Racemic mixtures can also be resolved into their component enantiomers by well- known methods, such as chiral-phase liquid chromatography or crystallizing the compound in a chiral solvent. Stereoselective syntheses, a chemical or enzymatic reaction in which a single reactant forms an unequal mixture of stereoisomers during the creation of a new stereocenter or
during the transformation of a pre-existing one, are well known in the art. Stereoselective syntheses encompass both enantio- and diastereoselective transformations, and may involve the use of chiral auxiliaries. For examples, see Carreira and Kvaemo, Classics in Stereoselective Synthesis, Wiley-VCH: Weinheim, 2009.
[00038] The compounds disclosed herein can exist in solvated as well as unsolvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the disclosure embrace both solvated and unsolvated forms. In one embodiment, the compound is amorphous. In one embodiment, the compound is a single polymorph. In another embodiment, the compound is a mixture of polymorphs. In another embodiment, the compound is in a crystalline form.
[00039] The disclosure also embraces isotopically labeled compounds of the disclosure which are identical to those recited herein, except that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine, such as 2H, 3H, 13C, 14C, 15N, 18O, 170, 31P, 32P, 35S, 18F, and 36C1, respectively. For example, a compound of the disclosure may have one or more H atom replaced with deuterium.
[00040] Certain isotopically-labeled disclosed compounds (e.g., those labeled with 3H and 14C) are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., 3H) and carbon- 14 (i.e., 14C) isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., 2H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances. Isotopically labeled compounds of the disclosure can generally be prepared by following procedures analogous to those disclosed in the examples herein by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.
[00041] The term “prodrug” refers to compounds that are transformed in vivo to yield a disclosed compound or a pharmaceutically acceptable salt, hydrate or solvate of the compound. The transformation may occur by various mechanisms (such as by esterase, amidase, phosphatase, oxidative and or reductive metabolism) in various locations (such as in the intestinal lumen or upon transit of the intestine, blood or liver). Prodrugs are well known in the
art (for example, see Rautio, Kumpulainen, et al, Nature Reviews Drug Discovery 2008, 7, 255). For example, if a compound of the disclosure or a pharmaceutically acceptable salt, hydrate or solvate of the compound contains a carboxylic acid functional group, a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a group such as (Ci-x)alkyl. (C2-i2)alkylcarbonyloxymethyl, l-(alkylcarbonyloxy)ethyl having from 4 to 9 carbon atoms, 1 -methyl- 1 -(alkylcarbonyloxy) -ethyl having from 5 to 10 carbon atoms, alkoxy carbonyloxymethyl having from 3 to 6 carbon atoms, 1 -(alkoxy carbonyloxy)ethyl having from 4 to 7 carbon atoms, 1 -methyl- 1 -(alkoxy carbonyloxy)ethyl having from 5 to 8 carbon atoms, N-(alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms, l-(N-(alkoxycarbonyl)amino)ethyl having from 4 to 10 carbon atoms, 3-phthalidyl, 4-crotonolactonyl, gamma-butyrolacton-4-yl, di-N,N-(Ci-2)alkylamino(C2-3)alkyl (such as [3- dimethylaminoethyl), carbamoyl-(Ci-2)alkyl, N,N-di(Ci-2)alkylcarbamoyl-(Ci-2)alkyl and piperidino-, pyrrolidine- or morpholino(C2-3)alkyl.
[00042] Similarly, if a compound of the disclosure contains an alcohol functional group, a prodrug can be formed by the replacement of the hydrogen atom of the alcohol group with a group such as (Ci-6)alkylcarbonyloxymethyl, l-((Ci-6)alkylcarbonyloxy)ethyl, l-methyl-l-((Ci- 6)alkylcarbonyloxy)ethyl (Ci-6)alkoxycarbonyloxymethyl, N-(Ci-6)alkoxycarbonylaminomethyl, succinoyl, (Ci-e)alkylcarbonyl, a-amino(Ci-4)alkylcarbonyl, arylalkylcarbonyl and a- aminoalkylcarbonyl, or a-aminoalkylcarbonyl-a-aminoalkylcarbonyl, where each > - aminoalkylcarbonyl group is independently selected from the naturally occurring L-amino acids, P(O)(OH)2, -P(O)(O(Ci-e)alkyl)2or glycosyl (the radical resulting from the removal of a hydroxyl group of the hemiacetal form of a carbohydrate).
[00043] If a compound of the disclosure incorporates an amine functional group, a prodrug can be formed, for example, by creation of an amide or carbamate, an N-alkylcarbonyloxyalkyl derivative, an (oxodioxolenyl)methyl derivative, an N-Mannich base, imine or enamine. In addition, a secondary amine can be metabolically cleaved to generate a bioactive primary amine, or a tertiary amine can metabolically cleaved to generate a bioactive primary or secondary amine. For examples, see Simplicio, et al., Molecules 2008, 13, 519 and references therein.
[00044] The term "warhead" or "warhead group" as used herein refers to a functional group present on a compound wherein that functional group is capable of reversibly or irreversibly participating in a reaction with a protein, e.g., 3C or 3CL protease (e.g., with a cysteine on the
protease such as Cys 145). Warheads may, for example, form covalent bonds with the protein, or may create stable transition states, or be a reversible or an irreversible alkylating agent. For example, the warhead moiety can be a functional group on an inhibitor that can participate in a bond-forming reaction, wherein a new covalent bond is formed between a portion of the warhead and a donor, for example an amino acid residue of a protein. In embodiments, the warhead is an electrophile and the “donor” is a nucleophile such as the side chain of a cysteine residue. As provided herein, a warhead may include a nitrile group. For example, nitriles may be reversible covalent warheads for cysteine protease inhibition. For example, where the mechanism of action may involve a formation of reversible covalent bond between the nitrile and the active cysteine to form a thioimidate adduct. Reaction of cysteine of glutathione or other proteins is generally reversible, while the reaction with cysteine or aminoethylthiols generally irreversibly forms a thiazolidine adduct. It can be appreciated that contemplated compounds herein may be a reversible or an irreversible inhibitor. It will be appreciated to one of skilled in the art that the compounds disclosed herein that include the warheads above also contemplate the precursors to those compounds, for example, where a cyano moiety involved in a warheads may be replaced with e.g., a halo moiety.
[00045] It will be appreciated to one of skilled in the art that the compounds disclosed herein can also irreversibly bind, or may otherwise inhibit e.g., a virus protein via any other mechanism of action.
[00046] The term "inhibitor" as used herein refers to a compound that binds to and /or inhibits a target protease with measurable affinity.
[00047] The term “reversible” or "reversible inhibitor" as used herein refers to a protease inhibitor that associates with a protease in such a way as to inhibit the activity of the protease while the protease and inhibitor are bound, but does not associate with a protease in such a way as to inhibit the activity of the protease when the protease and inhibitor are no longer bound. Reversible inhibitors can affect inhibition by competing with substrate for binding to the active site of the protease (competitive reversible inhibitor), or by associating with the protease bound to its substrate in a way to make the complex inactive (uncompetitive reversible inhibitor), or by associating with the protease and/or protease-substrate complex in a way that inhibits the activity of either and/or both.
[00048] As used herein, the term “irreversible” or “irreversible inhibitor” refers to
an inhibitor (i.e., a compound) that can be covalently bonded to a target protease in a substantially non-reversible manner. An irreversible inhibitor will remain substantially bound to the target protease once covalent bond formation has occurred. Irreversible inhibitors usually display time dependency, whereby the degree of inhibition increases with the time with which the inhibitor is in contact with the enzyme. In certain embodiments, an irreversible inhibitor will remain substantially bound to target protease once covalent bond formation has occurred and will remain bound for a time period that is longer than the life of the protein.
[00049] As used herein and unless otherwise specified, the term “purity” or “pure” means one or more of the following: chiral purity, enantiomeric purity/enantiomerically pure, free of impurities (e.g., primary amide impurities, epimer impurities, and isomer impurities), substantially pure, and purity of any intermediates in the process of preparing a compound (for example, a compound of Formula I).
I. Viral Protease Inhibitor Compounds
[00051] In various embodiments, provided herein is a process for the preparation of a compound of Formula I:
Formula I; comprising: providing a compound of Formula VI:
Formula VI; coupling the compound of Formula VI with a compound of Formula VII, or a salt thereof:
Formula VIII:
Formula VIII; amidating the compound of Formula VIII to produce a compound of Formula IX:
Formula IX; and dehydrating the compound of Formula IX to provide the compound of Formula I; wherein R1 is selected from the group consisting of H, halogen, Ci-ealkyl, and Ci-ealkoxy; R2a, R2b, R2c, and R2d are independently, for each occurrence, selected from the group consisting of H, halogen, Ci- ealkyl, and Ci-ealkoxy; R3 is selected from the group consisting of methyl, ethyl, propyl, and butyl; Rl is independently, for each occurrence, H or Ci-ealkyl; or two Rl may be
taken, together with the carbon to which they are attached, to form a Cs-C locycloalkyl; and n is 0 or 1.
[00052] In various embodiments, provided herein is a process for the preparation of a compound of Formula I:
Formula I; comprising: coupling a compound of Formula VI with a compound of Formula VII, or a salt thereof:
Formula VIII; amidating the compound of Formula VIII to produce a compound of Formula IX:
Formula IX; and dehydrating the compound of Formula IX to provide the compound of Formula I; wherein R1 is selected from the group consisting of H, halogen, Ci-ealkyl, and Ci-ealkoxy; R2a, R2b, R2C, and R2d are independently, for each occurrence, selected from the group consisting of H, halogen, Ci-ealkyl, and Ci-ealkoxy; R3 is selected from the group consisting of methyl, ethyl, propyl, and butyl; Rl is independently, for each occurrence, H or Ci-ealkyl; or two Rl may be taken, together with the carbon to which they are attached, to form a Cs-Ciocycloalkyl; and n is 0 or 1.
[00053] In various embodiments, R1 is H.
[00054] In some embodiments, R2a, R2b, and R2c are H. In some embodiments, R2d is halogen. In some embodiments, R2a, R2b, and R2c are H; and R2dis chloro.
[00055] In various embodiments, R3 is methyl.
[00056] In some embodiments, Rl is H.
[00057] In some embodiments, Rl is methyl. In some embodiments, Rl selected from the group consisting of methyl, ethyl, propyl, and butyl.
[00058] In some embodiments, two Rl are taken, together with the carbon to which they are attached, to form a cyclopropyl, cyclobutyl, or oxetanyl.
[00059] In various embodiments, n is 1. In various embodiments, n is 0.
[00060] In embodiments, providing the compound of Formula VI comprises: providing a compound of Formula IV :
Formula IV; and activating the compound of Formula IV to provide the compound of Formula VI; wherein LG is a leaving group.
[00061] In embodiments, the compound of Formula VI is prepared by activating the compound of Formula IV to provide the compound of Formula VI; wherein LG is a leaving group.
[00062] In some embodiments, LG is halogen.
[00063] In some embodiments, LG is selected from the group consisting of fluoro, chloro, bromo, and pentafluorophenolate.
[00064] In some embodiments, LG is chloro.
[00065] In embodiments, providing the compound of Formula VI comprises: halogenating a compound of Formula III: Formula III; to produce a compound of Formula IV :
Formula IV, wherein LG is a halogen; and amidating the compound of Formula IV to provide the compound of Formula VI.
[00066] In embodiments, the compound of Formula VI is prepared by halogenating a compound of Formula III:
Formula III; to produce a compound of Formula IV :
Formula IV, wherein LG is a halogen; and amidating the compound of Formula IV to provide the compound of Formula VI.
[00067] In embodiments, LG is selected from the group consisting of fluoro, bromo, and chloro.
[00068] In embodiments, coupling the compound of Formula VI with the compound of Formula VII, or a salt thereof, comprises contacting the compound of Formula VI with the compound of Formula VII, or a salt thereof, in the presence of a coupling reagent.
[00069] In some embodiments, the coupling reagent is 2-(lH-Benzotriazole-l-yl)-l, 1,3,3- tetramethylaminium tetrafluoroborate (TBTU).
[00070] In an embodiment, coupling the compound of Formula VI with the compound of Formula VII, or a salt thereof, further comprises a base.
[00072] In some embodiments, the salt of the compound of Formula VII is:
[00073] In some embodiments, the base is N,N-diisopropylethylamine (DIPEA).
[00074] In some embodiments, amidating the compound of Formula VIII comprises contacting the compound of Formula VIII with NHs. In some embodiments, amidating the compound of Formula VIII comprises contacting the compound of Formula VIII with NHs and 1 ,8-diazabicyclo(5.4.0)undec-7 -ene (DBU) .
[00075] In some embodiments, dehydrating the compound of Formula IX comprises contacting the compound of Formula IX with a trifluoroacetic acid anhydride; a propanephosphonic acid anhydride; or a propanephosphonic acid anhydride and N- methylmorpholine .
[00076] In some embodiments, dehydrating the compound of Formula IX comprises contacting the compound of Formula IX with a trifluoroacetic acid anhydride.
[00077] In some embodiments, dehydrating the compound of Formula IX comprises contacting the compound of Formula IX with a propanephosphonic acid anhydride. In some embodiments, dehydrating the compound of Formula IX comprises contacting the compound of Formula IX with A'-mc thy 1 morpholine. In some embodiments, dehydrating the compound of Formula IX comprises contacting the compound of Formula IX with a propanephosphonic acid anhydride and A'-mcthyl morpholine.
[00078] In some embodiments, halogenating the carboxylic acid represented by Formula III comprises contacting the compound of Formula III with (COC1)2 in the presence of a solvent and a co-solvent.
[00079] In embodiments, the solvent is dichloromethane. In embodiments, the solvent is tertbutyl methyl ether. In embodiments, the solvent is a mixture of dichloromethane and tert-butyl methyl ether.
[00080] In embodiments, the co-solvent is dimethylformamide.
[00081] In embodiments, amidating the compound of Formula IV comprises contacting the compound of Formula IV with (S)-2-amino-3-cyclopropylpropanoic acid in the presence of a base.
[00082] In some embodiments, the base is Na2COs.
[00083] In some embodiments, providing the compound of Formula III comprises:
forming a salt of a compound of Formula III:
Formula III; isolating the salt of the compound of Formula III; and contacting the salt of the compound of Formula III with an acid to produce a pure compound of Formula III.
[00084] In some embodiments, the compound of Formula III is prepared by isolating the salt of the compound of Formula III; and contacting the salt of the compound of Formula III with an acid to produce a pure compound of Formula III.
[00085] In some embodiments, forming the salt of the compound of Formula III comprises contacting the compound of Formula III with dicyclohexylamine.
[00086] In some embodiments, the acid is phosphoric acid.
[00087] In some embodiments, the compound of Formula I is provided in greater than about
99% purity.
[00088] In embodiments, the purity is chiral purity.
[00089] In some embodiments, the compound of Formula I is:
the compound of Formula VI is:
the compound of Formula VII, or salt thereof, is:
the compound of Formula VIII is:
the compound of Formula IX is:
[00091] In embodiments, the compound of Formula I is provided in greater than about 99% purity.
[00092] In some embodiments, the purity is chiral purity.
[00093] In some embodiments, the compound of Formula IV is:
[00095] Also provided herein, is a compound represented by:
r pharmaceutically acceptable salt thereof, prepared by the process described herein.
[00096] Also provided herein, is a purified compound of Formula I:
Formula I, prepared by the process described herein.
[00097] In some embodiments, the compound of Formula I is
[00098] In some embodiments, the compound has 98% or 99% purity. In some embodiments, the compound has 98%. In some embodiments, the compound has 99%.
[00099] In some embodiments, the compound has greater than 95% purity (e.g., greater than 96%, 97%, 98%, or 99% purity).
[000100] In some embodiments, the purity is chiral purity.
[000101] In some embodiments, an impurity is removed from the compound of any one of Formula I, Formula II, Formula III, Formula IV, Formula VI, Formula VII or salt thereof, Formula VIII, and Formula IX is purified prior to using the compound in any of the processes described herein. In some embodiments, water is removed from the compound of any one of Formula I, Formula II, Formula III, Formula IV, Formula VI, Formula VII or salt thereof, Formula VIII, and Formula IX is purified prior to using the compound in any of the processes described herein. In some embodiments, the compound of any one of Formula I, Formula II, Formula III, Formula IV, Formula VI, Formula VII or salt thereof, Formula VIII, and Formula IX is dried prior to using the compound in any of the processes described herein.
[000102] In some embodiments, the compound of any one of Formula I, Formula II, Formula III, Formula IV, Formula VI, Formula VII or salt thereof, Formula VIII, and Formula IX is purified prior to using the compound in any of the processes described herein. In some embodiments, purification comprises distillation, precipitation, crystallization, extraction, chromatography, or any combination thereof.
[000103] Procedures for making compounds described herein are provided below with reference to Schemes 1-7. In the reactions described below, it may be necessary to protect reactive functional groups (such as hydroxyl, amino, thio or carboxyl groups) to avoid their unwanted participation in the reactions. The incorporation of such groups, and the methods required to introduce and remove them are known to those skilled in the art (for example, see Greene, Wuts, Protective Groups in Organic Synthesis. 4th Ed. (2007)). The deprotection step
may be the final step in the synthesis such that the removal of protecting groups affords compounds of Formula I, as disclosed herein. Starting materials used in the following schemes can be purchased or prepared by methods described in the chemical literature, or by adaptations thereof, using methods known by those skilled in the art. The order in which the steps are performed can vary depending on the groups introduced and the reagents used, but would be apparent to those skilled in the art.
EXAMPLES
[000104] The procedures disclosed herein can be conducted in a number of ways based on the teachings contained herein and synthetic procedures known in the art. In the description of the synthetic methods described below, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and workup procedures, can be chosen to be the conditions standard for that reaction, unless otherwise indicated. It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule should be compatible with the reagents and reactions proposed. Substituents not compatible with the reaction conditions will be apparent to one skilled in the art, and alternate methods are therefore indicated. The starting materials for the examples are either commercially available or are readily prepared by standard methods from known materials.
[000105] At least some of the compounds identified as intermediates e.g., as part of a synthetic scheme disclosed herein are contemplated as compounds of the disclosure.
[000106] Chemical shifts in the JH NMR spectra are expressed in ppm relative to tetramethylsilane. The following abbreviations have been used: br = broad signal, s = singlet, d = doublet, dd = double doublet, dt = double triplet, ddd = double double doublet, t = triplet, td = triple doublet, tdd = triple double doublet, q = quartet, m = multiplet.
Example 1. A Process Description for the Preparation of 7-chloro-N-((S)-l-(((S)-l-cyano-2- ((S)-2-oxopiperidin-3-yl)ethyl)amino)-3-cyclopropyl-l-oxopropan-2-yl)-lH-indole-2- carboxamide
Synthesis of7-chloro-lH-indole-2-carbonyl chloride (12):
[000108] 7-Chloro- l//-indolc-2 -carboxylic acid was purified and used (Scheme 1, Step 1). 7-
Chloro- lH-indole-2 -carboxylic acid (10.0 kg) and dichloromethane (200 L) were charged into a reactor under N2 atmosphere at about 10-20 °C. Then, dimethylformamide (299g, 0.08 eq) was charged into the reactor under N2 at about 10-20 °C. (COC1)2 (13.0 kg, 2.00 eq) was charged into the reaction mixture drop-wise at about 5-10 °C in about 2-3 hours. After the addition, the mixture was stirred at about 10-20 °C for about another 6 hours. The mixture was filtered and the filter cake was rinsed with dichloromethane (20.0 L). The filtrate was concentrated to afford 7-chloro-lH-indole-2 -carbonyl chloride (11.0 kg).
Synthesis of (S)-2-(7-chloro-lH-indole-2-carboxamido)-3-cyclopropylpropanoic acid (14):
[000109] Dichloromethane (88.0 L) and water (110 L) were charged into a reactor under N2 atmosphere at 10-20 °C. Then, Na2COs (21.8 kg, 4.00 eq) were charged into the reactor under N2 at about 10-20 °C. (S)-2-Amino-3-cyclopropylpropanoic acid (7.30 kg, 1.10 eq) was charged into the reactor under N2 at about 10-20 °C, and then the reaction mixture was cooled to about 0- 5 °C. The internal temperature of the reactor was kept at about 0-5 °C, and then a solution of 7- chloro- lH-indole-2 -carbonyl chloride (11.0 kg) in dichloromethane (88.0 L) was added dropwise into the reaction mixture over 3 hours. After the addition, the reaction mixture was stirred at about 0-5 °C for 1 hour. The reaction mixture was warmed to about 10-20 °C, and then water (22.0 L) was charged into the reaction mixture. The resulting mixture was stirred at about 10- 20 °C for 30 minutes, and then the mixture was settled for additional 30 minutes, thereby forming two layers. Extraction was performed by charging tetrahydrofuran (110 L) to the aqueous layer and charging HC1 (aq.) (3 mol/L) to adjust the pH to about 1 at a temperature of about 10-20 °C, and then the reaction mixture was stirred for 30 minutes. The resulting two layers were separated. The organic layer was concentrated to about 33.0 L, and the residue was charged to another reactor and heated to a temperature of about 70-80 °C. n-Heptane (66.0 L) was charged drop-wise into the reactor at about 70-80 °C, and then the reaction mixture was stirred at about 70-80 °C for 4 hours. The reaction mixture was cooled to 10-20 °C slowly over 8 hours, and then the mixture was stirred at about 10-20 °C for additional 12 hours. The filtrate cake was obtained after filtration of the reaction mixture, and then the filter cake was rinsed with water (110 L). The filter cake was dried under vacuum to obtain A)-2-(7-chloro- 1 H-indolc-2- carboxamido)-3 -cyclopropylpropanoic acid (13.0 kg).
Synthesis of methyl (S)-2-((S)-2-(7-chloro-l H-indole-2-carboxamido)-3- cyclopropylpropanamido)-3-( (S)-2-oxopiperidin-3-yl)propanoate (16)
[000110] Dichloromethane (260 L) and (S)-2-(7-chloro-l H-indole-2-carboxamido)-3- cyclopropylpropanoic acid (13.0 kg) were charged into a reactor under N2 atmosphere at about 10-20 °C. 2-(lH-Benzotriazole-l-yl)-l, 1, 3, 3-tetramethyluronium tetrafluoroborate (TBTU, 1.20 eq) was charged into the reactor under N2 at about 10-20 °C, and then methyl (S)-2-amino-3- ((S)-2-oxopiperidin-3-yl)propanoate ( 1. 18 eq) was charged into the reactor under N2 at about 10- 20 °C. The reactor was rinsed with dichloromethane (65.0 L) under N2 at 10-20 °C, and then the
reaction mixture was cooled to about -5 to 5 °C. DIPEA (3.50 eq) was charged into the reaction mixture drop-wise over 3 hours, and then the reaction mixture was stirred at about -5 to 5 °C for additional 6 hours. 5 wt% NaHCOs solution (130 L) was charged into the reaction mixture at about -5 to 5 °C, and then the reaction mixture was warmed to about 10-20 °C. Dichloromethane (65.0 L) was charged into the mixture, and then the mixture was stirred at about 10-20 °C for 30 minutes and settled for additional 30 minutes. The resulting two layers were separated, and then about 0.6 mol/L HC1 (65.0 L) was charged into the organic layer. The mixture was stirred at about 10-20 °C for 30 minutes, and then settled for additional 30 minutes. The resulting two layers were separated, and the previous step was repeated. After separating the resulting two layers, a solution of about 10 wt% NaCl and 5 wt% NaHCOs (65.0 L) were charged into the organic layer, and then the mixture was stirred at 10-20 °C for 30 minutes and settled for additional 30 minutes. The resulting two layers were separated, and the organic layer was concentrated under vacuum (40-50 °C) to about 160 L. MeCN (260 L) was charged into the residue and the mixture was concentrated to about 160 L, and this step was repeated, followed by stirring of the mixture at about 15-25 °C for 4 hours. The mixture was filtered and the filter cake was rinsed with MeCN (39.0 L). The filter cake was dried under vacuum at about 40-45 °C to afford methyl (S)-2-((S)-2-(7-chloro- lH-indole-2-carboxamido)-3-cyclopropylpropanamido)-3- ((S)-2-oxopiperidin-3 -yl)propanoate .
Synthesis ofN-((S)-l-(((S)-l-amino-l-oxo-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)amino)-3- cyclopropyl-l-oxopropan-2-yl)-7-chloro-lH-indole-2-carhoxamide (17) and 7-chloro-N-((S)-l- (((S)-l-cyano-2-((S)-2-oxopiperidin-3-yl)ethyl)amino)-3-cyclopropyl-l-oxopropan-2-yl)-lH- indole-2-carhoxamide (18)
[000111] Methyl (S)-2-((S)-2-(7-chloro-lH-indole-2-carboxamido)-3- cyclopropylpropanamido)-3-((S)-2-oxopiperidin-3-yl)propanoate was reacted with NHs in methanol, and then purified to afford N-(/S)-l-(((S)-l-amino-l-oxo-3-(('lS)-2-oxopiperidin-3- yl)propan-2-yl)amino)-3-cyclopropyl-l-oxopropan-2-yl)-7-chloro-lH-indole-2-carboxamide, which was treated with trifluoroacetic acid anhydride and triethyl amine in tetrahydrofuran, and then purified to afford 7-chloro-N-((S)-l-(((S)-l-cyano-2-((S)-2-oxopiperidin-3-yl)ethyl)amino)- 3 -cyclopropyl- 1 -oxopropan-2-yl)- 1 H-indole -2-carboxamide .
Example 2. A Large-Scale Synthesis of 7-chloro-N-((S)-l-(((S)-l-cyano-2-((S)-2- oxopiperidin-3-yl)ethyl)amino)-3-cyclopropyl-l-oxopropan-2-yl)-lH-indole-2-carboxamide
Example 3. A Large-Scale Synthesis of 7-chloro-N-((S)-l-(((S)-l-cyano-2-((S)-2- oxopiperidin-3-yl)ethyl)amino)-3-cyclopropyl-l-oxopropan-2-yl)-lH-indole-2-carboxamide
Example 4. A Large-Scale Synthesis of 7-chloro-N-((S)-l-(((S)-l-cyano-2-((S)-2- oxopiperidin-3-yl)ethyl)amino)-3-cyclopropyl-l-oxopropan-2-yl)-lH-indole-2-carboxamide
Example 5. Preparation of methyl (S)-2-((tert-butoxycarbonyl)amino)-3-((S)-2- oxopiperidin-3-yl)propanoate
[000112] Charged a vessel with THL (10 L/kg) and dimethyl (tert-butoxycarbonyl)-L- glutamate (1.0 kg) and heat to 30 °C. Then added hexamethylphosphoramide (HMPA) (1.45 kg, 2.25 equiv.) and stir for about 10 minutes. The reaction mixture was then cooled to -77 ,5±7.5 °C and LiHMDS (IM in THL) (8.17 L/kg, 2.25 equiv.) was added slowly to the reaction mixture. After stirring for 30 minutes, 3 -bromopropionitrile (0.723 kg/kg, 1.5 equiv.) was added slowly over 2 hours at -77 ,5±7.5 °C. The reaction mixture was then stirred at -77 ,5±7.5 °C for 1 hour.
[000113] Then 5% citric acid monohydrate solution in water (5 L/kg) was added to the reaction mixturing while maintaining the temperature at -80 °C to -20 °C. The reaction mixture was then allowed to warm up to 25 °C and stirred for 1 hour at 25 °C. Ethyl acetate (10 L/kg) was added at 30 °C and then the mixture was stirred for about 10 minutes. Water (5 L/kg) was
then added at 25 °C and the mixture was stirred for about 10 minutes. Once the layers settled, they were separated. The organic layer was washed with water (3X, 5 L/kg). All combined aqueous layers were extracted with ethyl acetate (4X, 5 L/kg). The combined organic layers were then concentrated and then azeotroped with methyl tertiary-butyl ether (aka tert-butyl methyl ether; MTBE) (3 L/kg). The crude product was then charged with MTBE (5 L/kg) and silica gel (230-400) (1.5 kg/kg) was added and stirred for 1 hour at 25 °C. The mixture was fdtered through celite bed. Celite bed washed with MTBE (3 L/kg).
[000114] Methanol (3 L/kg) was then added to the collected product and stirred for about 5 minutes. The methanol layer was washed with n-heptane (2X, 5 L/kg). Methanol layer was then concentrated to afford dimethyl (2S,4S)-2-((tert-butoxycarbonyl)amino)-4-(2- cyanoethyl)pentanedioate .
[000115] A first reaction vessel was then charged with Raney Nickel (0.7 kg/kg) under inert atmosphere. A second reaction vessel was charged with methanol (8 L/kg) and dimethyl (2S,4S)-2-((tert-butoxycarbonyl)amino)-4-(2-cyanoethyl)pentanedioate (1.0 kg/kg), which was then passed through CUNO filter and washed with methanol (2 L/kg). This solution was then added to the first reaction vessel. Then triethylamine (TEA) (0.46 kg/kg) was added to the reaction mixture. The reaction mixture was then degassed with argon, followed by hydrogen. Hydrogen pressure was applied at 70-73 psi with stirring at 25 °C. Then the reaction mixture was heated to 50 °C for at least 16 hours, maitaining 70-73 psi of hydrogen pressure.
[000116] The reaction mixture was then cooled to 25 °C and filtered. The bed was washed with methanol (2 L/kg). The filtrate was concentrated to about 3 vol of methanol and then washed with n-heptane (2X; 5 L/kg). The methanol layer was concentrated to afford methyl (S)- 2-((tert-butoxycarbonyl)amino)-3-((S)-2-oxopiperidin-3-yl)propanoate.
[000117] Yield: 2.0 kg of dimethyl (tert-butoxycarbonyl)-L-glutamate afforded 1.62 kg (68%) of crude dimethyl (2S,4S)-2-((tert-butoxycarbonyl)amino)-4-(2-cyanoethyl)pentanedioate.
[000118] Yield: 1.57 ,g of crude dimethyl (2S,4S)-2-((tert-butoxycarbonyl)amino)-4-(2- cyanoethyl)pentanedioate afforded 1.1 kg (77%) of crude methyl (S)-2-((tert- butoxycarbonyl)amino)-3-((S)-2-oxopiperidin-3-yl)propanoate.
[000119] Crude methyl (S)-2-((tert-butoxycarbonyl)amino)-3-((S)-2-oxopiperidin-3- yl)propanoate was purified as follows. First, the crude product was azeotroped with 2-methyl THF (3 L/kg). After diluting with 2-methyl THF (2.5 L/kg) under inert atmosphere, the reaction
mixture was cooled to 5 °C. Then 4 N HCI was added and the reaction mixture was stirred for 1 hour. Then the reaction mixture was filtered under nitrogran atmosphere to obtain methyl HCI salt of (S)-2-((tert-butoxycarbonyl)amino)-3-((S)-2-oxopiperidin-3-yl)propanoate. This salt was then added to pre-cooled ethyl acetate (5 U/kg) at 5 °C. Then aqueous sodium bicarbonate was added and stirred for 30 minutes. The layers were separated, and the aqueous layer was extracted with ethyl acetate (2 U/kg; 5X). Then 10 w/w% silica gel was added to the organic layer and stirred for 30 minutes. This was then filtered and washed with ethyl acetate (5 U/kg). The organic layer was azeotroped with MTBE (2 L/kg; 2X). Then the concentrated product was dissolved in MTBE (2 L/kg), which was then stirred and then washed with n-heptane. The purified product was dried at 40 °C for 8 hours to afford purified methyl (S)-2-((tert- butoxycarbonyl)amino)-3-((S)-2-oxopiperidin-3-yl)propanoate.
[000120] Yield: 0.45 kg and 0.5 kg of crude methyl (S)-2-((tert-butoxycarbonyl)amino)-3- ((S)-2-oxopiperidin-3-yl)propanoate afforded 0.14 kg (35%) and 0.18 kg (36%, respectively, of purified methyl (S)-2-((tert-butoxycarbonyl)amino)-3-((S)-2-oxopiperidin-3-yl)propanoate.
Example 6. Preparation of HC1 salt of methyl (S)-2-amino-3-((S)-2-oxopiperidin-3- yl)propanoate (HC1 salt of 15)
2 HCI salt of 15 HCI salt of 15
[000121] Under inert atmosphere, charged a vessel with methyl (S)-2-((tert- butoxycarbonyl)amino)-3-((S)-2-oxopiperidin-3-yl)propanoate (1.0 kg). Used mechanical stirrer, condenser, and temperature probe. Then added ethyl acetate (EtOAc) (4.51 kg, 5 U/kg, 5V) and began agitation. Then added 2 N HCI in ethyl acetate (12.5 L, 7.5 equiv.) to the reaction vessel at 25 °C. Stirred for a minimum of 4 hours at 25 °C. Then the reaction mixture was filtered under inert atmosphere, and the material was dried at 50 °C for 7-8 hours to obtain
2HC1 salt of methyl (S)-2-((tert-butoxycarbonyl)amino)-3-((S)-2-oxopiperidin-3-yl)propanoate (2HC1 salt of 15).
[000122] Yield: 100 g of methyl (S)-2-((tert-butoxycarbonyl)amino)-3-((S)-2-oxopiperidin-3- yl)propanoate afforded 79 g of 2HC1 salt of methyl (S)-2-((tert-butoxycarbonyl)amino)-3-((S)-2- oxopiperidin-3-yl)propanoate (2HC1 salt of 15) (86%).
[000123] Then under inert atmosphere at 0 °C, 2HC1 salt of methyl (S)-2-((tert- butoxycarbonyl)amino)-3-((S)-2-oxopiperidin-3-yl)propanoate (2HC1 salt of 15) and isopropanol: water (98.5: 1.5, 8V) were added to a vessel fitted with a mechanical stirrer, condenser, and temperature probe at 0 °C. The reaction mixture was stirred for 16 hours at 0 °C. Then the reaction mixture was filtered under inert atmosphere and washed with isopropanol (IPA):water (98.5: 1.5, IV). The isolated product was dried in vacuo at 45 °C for 12 hours to afford HC1 salt of methyl (S)-2-((tert-butoxycarbonyl)amino)-3-((S)-2-oxopiperidin-3- yl)propanoate (HC1 salt of 15).
[000124] Yield: 100 g of methyl (S)-2-((tert-butoxycarbonyl)amino)-3-((S)-2-oxopiperidin-3- yl)propanoate afforded 49 g of HC1 salt of methyl (S)-2-((tert-butoxycarbonyl)amino)-3-((S)-2- oxopiperidin-3-yl)propanoate (HC1 salt of 15) (62%).
Example 7. Preparation of 7-chloro-N-((S)-l-(((S)-l-cyano-2-((S)-2-oxopiperidin-3- yl)ethyl)amino)-3-cyclopropyl-l-oxopropan-2-yl)-lH-indole-2-carboxamide
Synthesis of (S)-2-(7-chloro-lH-indole-2-carboxamido)-3-cyclopropylpropanoic acid (14)'.
[000125] 7 -Chloro- lH-indole-2 -carboxylic acid (10) was charged (100 g, 1.00 equivs. /parts)
(0.99 - 1.01 X) into a first vessel. Then MTBE (740 g, 7.4 parts) was added, followed by DMF (3.00 g, 0.030 parts). The temperature was adjusted to 15 °C. Then oxalyl chloride (84 g, 0.84 parts) was added dropwise at 15 °C for not less than 2 hours. Then the temperature was adjusted to 25 °C, and the first reaction mixture was stirred for 2 hours.
[000126] A second vessel was charged with (S)-2-amino-3-cyclopropylpropanoic acid (13) (77 g, 0.77 X) and Na2COs (163 g, 1.63 parts). Then water (300 g, 3.0 parts) and MTBE (590 g, 5.9 parts) are added to the second vessel. The temperature was adjusted to 15 °C.
[000127] Then the reaction mixture from the first vessel was added to the second vessel at 15 °C dropwise. The resulting reaction mixture was stirred for 2 hours at 15 °C.
[000128] The reaction mixture was then cooled to 15 °C, and 3N HC1 (6-9X) was added to adjust the pH to 1. The reaction mixture was then stirred for 1 h at 15 °C. After letting stand for 30 minutes, the lower aqueous layer was discharged, and the organic layer was filtered through CUNO filter. Product was isolated by washing with ^-heptane. The product was mixed with water, heated, and stirred. Product was isolated by filtration, washed with water and dried in the oven in vacuo.
[000129] Yield: 100 g batch afforded 136 g (77%) of (S)-2-(7-chloro-lH-indole-2- carboxamido)-3 -cyclopropylpropanoic acid (14).
Synthesis of methyl (S)-2-((S)-2-(7-chloro-lH-indole-2-carboxamido)-3- cyclopropylpropanamido)-3-( (S)-2-oxopiperidin-3-yl)propcmoate (16):
[000130] Under nitrogen atmosphere at 20 °C, (S)-2-(7-chloro-lH-indole-2-carboxamido)-3- cyclopropylpropanoic acid (14) (1.0 kg) was added to a vessel fitted with a mechanical stirrer, a condenser, and a temperature probe. Then HC1 salt of methyl (S)-2-amino-3-((S)-2- oxopiperidin-3-yl)propanoate (HC1 salt of 15) (0.78 kg, 1.20 equiv) was added to reaction vessel at 20 °C. Then 2-(lH-Benzotriazole-l-yl)-l,l,3,3-tetramethylaminium tetrafluoroborate (TBTU) (1.25 kg, 1.20 equiv) and dichloromethane (DCM) (20.0 L, 20 L/kg) was added, and the reaction vessel was cooled to 7-12 °C. Then N,N- diisopropylethylamine (1.42 L, 2.47 equiv.) in dichloromethane (2.00 L, 2.0 L/kg) was added to the vessel at 7-12 °C over a minimum of 2.5 hours. The reaction was stirred for 3-3.5 hours.
[000131] Then 5% NaHCOs (5.0 L) was added to the reaction vessel while maintaining the termpature at 13-18 °C over 15 minutes. Then DCM (5 L) was added and the reaction mixture was warmed to 20-25 °C. The biphasic mixture was stirred for minimum 15 minutes. The organic and aqueous layers were separated. The organic layer was stirred with 0.6 M aqueous HC1 (5.0 L) and DCM (1.0 L). The layers were again separated, and the organic layer was again
stirred with 0.6 M aq. HC1 (5 L). The layers were separated, and the organic layer was stirred with 1: 1 5% aq. NaHCOs and 28 % aq. NaCl (5 L). The layers were separated, and the organic layer was concentrated. To the concentrate was added acetonitrile (12 L), which was then cooled to 18 °C. This was concentrated, and the suspended solids were collected via filtration. The product was dried under vaccum at 40-45 °C.
[000132] Yield: 1 kg of (S)-2-(7-chloro-lH-indole-2-carboxamido)-3-cyclopropylpropanoic acid (14) afforded 1.43 kg (90%) of methyl (S)-2-((S)-2-(7-chloro-lH-indole-2-carboxamido)-3- cyclopropylpropanamido)-3-((S)-2-oxopiperidin-3-yl)propanoate (16).
Synthesis ofN-((S)-l-(((S)-l-amino-l-oxo-3-((S)-2-oxopiperidin-3-yl)propan-2-yl)amino)-3- cyclopropyl-1 -oxopropan-2-yl)-7-chloro-lH-indole-2-carboxamide (17):
[000133] To an inert reactor at < 30 °C, charged methyl (S)-2-((S)-2-(7-chloro-lH-indole-2- carboxamido)-3-cyclopropylpropanamido)-3-((S)-2-oxopiperidin-3-yl)propanoate (16) (64.0 kg scale) to a vessel fitted with a mechanical stirrer, a condenser, and a temperature probe. Charged THF (227 kg, 5 L/kg) to the vessel at 20-25 °C, began agitation and held for 0.5 hours. Charged 7N NHs/MeOH (898 kg, 18 L/kg) to the vessel at 20-25 °C and rinsed forward with THF (29 kg, 0.5 L/kg). Charge l,8-diazabicyclo(5.4.0)undec-7-ene (DBU) (39.9 kg, 2.0 eq) to the vessel at 20-25 °C over 1.5 hours and rinsed forward with THF (29 kg, 0.5 L/kg). Heated the reaction mixture to 25-30 °C. Stirred the reaction for a minimum of 18 hours at 25-30 °C. Cooled reaction mixture to 10-15 °C and distilled under vacuum at < 35 °C until 11-12 L/kg (704-768 L) remained in vessel. Heated the reaction mixture to 45-50 °C with vigorous stirring for 1-2 hours to dislodge the solids stuck on the walls of the reactor. Cooled the mixture to 20-25 °C and then stirred the mixture for a minimum of 18 hours. Collected the suspended solid by filtration. Rinsed the residual solids in the vessel with methanol (152 kg, 3 L/kg). Washed the filter cake with the vessel rinse. Upon completion of the wash, maintain < 30 psi of nitrogen pressure on the filter for 6 h to de-liquor the solids. Dried the cake of product under vacuum at 40-45 °C until no further weight loss is observed.
[000134] Yield: 64 kg of methyl (S)-2-((S)-2-(7-chloro-lH-indole-2-carboxamido)-3- cyclopropylpropanamido)-3-((S)-2-oxopiperidin-3-yl)propanoate (16) afforded 52.894 kg (85%) of N-((S)- 1 -(((S)- 1 -amino- 1 -oxo-3-((S)-2-oxopiperidin-3 -yl)propan-2-yl)amino)-3 -cyclopropyl - l-oxopropan-2-yl)-7-chloro-lH-indole-2-carboxamide (17).
Synthesis of7-chloro-N-((S)-l-(((S)-l-cyano-2-((S)-2-oxopiperidin-3-yl)ethyl)amino)-3- cyclopropyl-l-oxopropan-2-yl)-lH-indole-2-carboxamide (18):
[000135] Under a nitrogen atmosphere at 28 °C, chargeed N-((S)-l-(((S)-l-amino-l-oxo-3- ((S)-2-oxopiperidin-3-yl)propan-2-yl)amino)-3-cyclopropyl-l-oxopropan-2-yl)-7-chloro-lH- indole-2 -carboxamide (17) (90 g) to a vessel fitted with a mechanical stirrer, a condenser, and a temperature probe. Charged 720 mb of anhydrous THF (8 V) and 270 m of EtOAc (3 V). Heated the reaction mixture to 28-32 °C. Charged JV-methylmorpholine (NMM) (96.1 g/104.4 mb, 5.0 equiv.) to the vessel at 28-32 °C over a minimum of 15 minutes followed by a line rinse of ethyl acetate (90 mb, 1.0 part). Heated the reaction mixture to 48-53 °C, target 50 °C. Charged propanephosphonic acid anhydride (TsP) as a 50% wt solution in EtOAc (423.2 g/395.5 mL, 3.5 equiv.) at 50-55 °C over 20 to 30 minutes followed by a line rinse of ethyl acetate (90 mb, 1.0 part) to the vessel at 50-55 °C. Stirred the reaction for 1.5 to 2 hours at 50-55 °C, target 53 °C.
[000136] Charged water (450 mL, 5V while maintaining the batch temperature at 20-43 °C. Stirred the biphasic mixture for a minimum of 15 minutes at 38-42 °C. Separated the layers. The lower aqueous layer was back extracted with EtOAC (360 mL, 4 V), agitated for 15-20 min at 20-43 °C. Separated the layers. Combined both organic layers at 38-43 °C. Charged 5% NaHCOs (450 mL, 5 V ) to the vessel maintaining temperature at 38-43 °C and stirred for 15-20 minutes. Separated the layers at 38-43 °C and discarded the lower aqueous layer. Charged 180 mL of EtOAC (2 V and 450 mL of water (5 parts) to the organic layer for 15-25 min at 38- 43 °C. Separated the layers. Kept the upper organic layer and discard the lower aqueous layer. Clarified the organic layer via polish filter. Washed the filter with prefiltered 180 mL of EtOAc (2 V) and combined with organic layer at 38-43 °C. Concentrated the batch to 900-990 mL (10- 1 IV) under reduced pressure at 38-43 °C. Charge dl350 mL (15 V) of prefiltered acetone while maintaining the temperature at 38-43 °C. Concentrated the batch to 900-990 mL (10-11 V) under reduced pressure at 38-43 °C. Charged 1350 mL (15 V) of prefiltered acetone while maintaining the temperature at 38-43 °C. Concentrated the batch to 900-990 mL (10-11 parts) under reduced pressure at 38-43 °C. Filtered. Washed the cake with 360 mL (4 V) of prefiltered acetone
[000137] The product (75 g) was transferred to a flask fitted with a mechanical stirrer, thermometer, condenser and N2. Charged 75 mL of prefiltered acetic acid (I V) and 75 mL of prefiltered acetone (I V). Charged 675 mL of prefiltered acetone (9 V) at 20-25 °C. Heated the slurry to 53-58 °C and stir at 53-58 °C for 24-25 hours. Slurry was cooled to 20-25° C over 1.5- 2 hours and stired for a minimum of 3 hours. Filtered. Washed with 300 mL of prefiltered acetone (4 V). Dried the solids under vacuum at 50-55 °C for minimum of 15 hours. Transferred the solids to a flask fitted with stirrer, thermometer and N2. Charged 1190 mL of prefiltered process water (17 V) and stir the slurry at 20-25 °C. Charged 1.05 g of seeds (0.015 V) in 14 mL of prefiltered process water (0.2 V) and rinse forward with 35 mL of prefiltered process water (0.5 part) at 20-25 °C. Stirred solids at 68-73 °C for 24-25 hours. Cooled the solids to 20-25 °C over 2.5-3 hours and stirred for a minimum 22 hours. Filtered. Washed the cake with 280 mL of prefiltered process water (4 V). Dried the wet solids (looks like a paste) under vacuum at 58- 63 °C for a minimum of 24 hours.
[000138] Yield: 90 g of N-((S)-l-(((S)-l-amino-l-oxo-3-((S)-2-oxopiperidin-3-yl)propan-2- yl)amino)-3-cyclopropyl-l-oxopropan-2-yl)-7-chloro-lH-indole-2-carboxamide (17) afforded 63.3 g (80%) of 7-chloro-N-((S)-l-(((S)-l-cyano-2-((S)-2-oxopiperidin-3-yl)ethyl)amino)-3- cyclopropyl- 1 -oxopropan-2-yl)- lH-indole-2 -carboxamide (18).
INCORPORATION BY REFERENCE
[000139] All publications and patents mentioned herein, including those items listed below, are hereby incorporated by reference in their entirety for all purposes as if each individual publication or patent was specifically and individually incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.
EQUIVALENTS AND SCOPE
[000140] In the claims, articles such as “a,” “an,” and “the” may mean one or more than one unless indicated to the contrary or otherwise evident from the context. Claims or descriptions that include “or” between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context.
The invention includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process. The invention includes embodiments in which more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process.
[000141] Furthermore, the invention encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, and descriptive terms from one or more of the listed claims is introduced into another claim. For example, any claim that is dependent on another claim can be modified to include one or more limitations found in any other claim that is dependent on the same base claim. Where elements are presented as lists, e.g., in Markush group format, each subgroup of the elements is also disclosed, and any element(s) can be removed from the group. It should it be understood that, in general, where the invention, or aspects of the invention, is/are referred to as comprising particular elements and/or features, certain embodiments of the invention or aspects of the invention consist, or consist essentially of, such elements and/or features. For purposes of simplicity, those embodiments have not been specifically set forth in haec verba herein. It is also noted that the terms “comprising” and “containing” are intended to be open and permits the inclusion of additional elements or steps. Where ranges are given, endpoints are included. Furthermore, unless otherwise indicated or otherwise evident from the context and understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value or sub-range within the stated ranges in different embodiments of the invention, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise.
[000142] This application refers to various issued patents, published patent applications, journal articles, and other publications, all of which are incorporated herein by reference. If there is a conflict between any of the incorporated references and the instant specification, the specification shall control. In addition, any particular embodiment of the present invention that falls within the prior art may be explicitly excluded from any one or more of the claims. Because such embodiments are deemed to be known to one of ordinary skill in the art, they may be excluded even if the exclusion is not set forth explicitly herein. Any particular embodiment of the invention can be excluded from any claim, for any reason, whether or not related to the existence of prior art.
[000143] Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation many equivalents to the specific embodiments described herein. The scope of the present embodiments described herein is not intended to be limited to the above Description, but rather is as set forth in the appended claims. Those of ordinary skill in the art will appreciate that various changes and modifications to this description may be made without departing from the spirit or scope of the present invention, as defined in the following claims.
Claims
1. A process for the preparation of a compound of Formula I:
comprising: providing a compound of Formula VI:
Formula VII; thereby producing a compound of Formula VIII:
amidating the compound of Formula VIII to produce a compound of Formula IX:
Formula IX; and dehydrating the compound of Formula IX to provide the compound of Formula I; wherein
R1 is selected from the group consisting of H, halogen, Ci-ealkyl, and Ci-ealkoxy;
R2a, R2b, R2C, and R2d are independently, for each occurrence, selected from the group consisting of H, halogen, Ci-ealkyl, and Ci-ealkoxy;
R3 is selected from the group consisting of methyl, ethyl, propyl, and butyl;
Rl is independently, for each occurrence, H or Ci-ealkyl; or two Rl may be taken, together with the carbon to which they are attached, to form a C3-C10 cycloalkyl; and n is 0 or 1.
2. The process of claim 1, wherein R1 is H.
3. The process of claim 1 or 2, wherein R2a, R2b, and R2c are H; and R2dis chloro.
4. The process of any one of claims 1-3, wherein R3 is methyl.
5. The process of any one of claims 1-4, wherein Rl is H.
6. The process of any one of claims 1-4, wherein Rl is methyl.
7. The process of any one of claims 1-4, wherein two Rl are taken, together with the carbon to which they are attached, to form a cyclopropyl, cyclobutyl, or oxetanyl.
8. The process of any one of claims 1-7, wherein n is 1.
9. The process of any one of claims 1-8, wherein providing the compound of Formula VI comprises: providing a compound of Formula IV:
Formula IV; and activating the compound of Formula IV to provide the compound of Formula VI; wherein LG is a leaving group.
10. The process of claim 9, wherein LG is selected from the group consisting of fluoro, chloro, bromo, and pentafluorophenolate.
11. The process of claim 10, wherein LG is chloro.
12. The process of any one of claims 1-8, wherein providing the compound of Formula VI comprises: halogenating a compound of Formula III:
Formula IV, wherein LG is a halogen; and amidating the compound of Formula IV to provide the compound of Formula VI.
13. The process of claim 1, wherein coupling the compound of Formula VI with the compound of Formula VII, or salt thereof, comprises contacting the compound of Formula VI with the compound of Formula VII in the presence of a coupling reagent.
The process of claim 13, wherein the coupling reagent is 2-(lH-Benzotriazole-l-yl)- 1,1,3,3-tetramethylaminium tetrafluoroborate (TBTU). The process of claim 13 or 14, wherein coupling the compound of Formula VI with the compound of Formula VII, or salt thereof, further comprises a base. The process of claim 15, wherein the base is N,N-diisopropylethylamine (DIPEA). The process of claim 1, wherein amidating the compound of Formula VIII comprises contacting the compound of Formula VIII with NHs or with NHs and 1,8- diazabicyclo(5.4 ,0)undec-7 -ene (DBU) . The process of claim 1, wherein dehydrating the compound of Formula IX comprises contacting the compound of Formula IX with a trifluoroacetic acid anhydride; a propanephosphonic acid anhydride; or a propanephosphonic acid anhydride and N- methylmorpholine . The process of claim 12, wherein halogenating the carboxylic acid represented by Formula III comprises contacting the compound of Formula III with (COC1)2 in the presence of a solvent and a co-solvent. The process of claim 19, wherein the solvent is dichloromethane, tert-butyl methyl ether, or a combination thereof. The process of claim 19, wherein the co-solvent is dimethylformamide. The process of claim 12, wherein amidating the compound of Formula IV comprises contacting the compound of Formula IV with (S)-2-amino-3-cyclopropylpropanoic acid in the presence of a base. The process of claim 22, wherein the base is Na2COs. The process of claim 12, wherein providing the compound of Formula III comprises: forming a salt of a compound of Formula III:
Formula III; isolating the salt of the compound of Formula III; and contacting the salt of the compound of Formula III with an acid to produce a pure compound of Formula III. The process of claim 24, wherein forming the salt of the compound of Formula III comprises contacting the compound of Formula III with dicyclohexylamine. The process of claim 24 or 25, wherein the acid is phosphoric acid. The process of any one of claims 1-26, wherein the compound of Formula I is provided in greater than about 98% purity. The process of any one of claims 1-27, wherein the compound of Formula I is provided in greater than about 99% purity. The process of claim 27 or 28, wherein the purity is chiral purity. The process of any one of claims 1-29, wherein the compound of Formula I is:
the compound of Formula VI is:
the compound of Formula VII, or a salt thereof, is:
the compound of Formula VIII is:
the compound of Formula IX is:
The process of claim 30, wherein the compound of Formula I is
The process of claim 30 or 31, wherein the compound of Formula I is provided in greater than about 99% purity. The process of claim 32, wherein the purity is chiral purity. The process of claim 9 or 12, wherein the compound of Formula IV is:
The process of claim 12 or 24, wherein the compound of Formula III is:
A compound represented by:
or pharmaceutically acceptable salt thereof, prepared by the process of any one of claims 1-35. A purified compound of Formula I:
Formula I; prepared by the process of any one of claims 1-35.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163246118P | 2021-09-20 | 2021-09-20 | |
US63/246,118 | 2021-09-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023044509A1 true WO2023044509A1 (en) | 2023-03-23 |
Family
ID=83903242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/076742 WO2023044509A1 (en) | 2021-09-20 | 2022-09-20 | Process for making cysteine protease inhibitors and compounds provided by that process |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023044509A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023205779A1 (en) * | 2022-04-22 | 2023-10-26 | Pardes Biosciences, Inc. | Process for making cysteine protease inhibitor intermediates |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017114509A1 (en) * | 2015-12-31 | 2017-07-06 | 中国科学院上海药物研究所 | Aldehyde and preparation and application thereof |
EP3835296A1 (en) * | 2018-08-09 | 2021-06-16 | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | Ketoamide compound and preparation method, pharmaceutical composition, and use thereof |
US11174231B1 (en) * | 2020-06-09 | 2021-11-16 | Pardes Biosciences, Inc. | Inhibitors of cysteine proteases and methods of use thereof |
WO2021252644A1 (en) * | 2020-06-09 | 2021-12-16 | Pardes Biosciences, Inc. | Inhibitors of cysteine proteases and methods of use thereof |
WO2022133588A1 (en) * | 2020-12-21 | 2022-06-30 | The Governors Of The University Of Alberta | Rna virus inhibitor compounds and uses thereof |
-
2022
- 2022-09-20 WO PCT/US2022/076742 patent/WO2023044509A1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017114509A1 (en) * | 2015-12-31 | 2017-07-06 | 中国科学院上海药物研究所 | Aldehyde and preparation and application thereof |
EP3835296A1 (en) * | 2018-08-09 | 2021-06-16 | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | Ketoamide compound and preparation method, pharmaceutical composition, and use thereof |
US11174231B1 (en) * | 2020-06-09 | 2021-11-16 | Pardes Biosciences, Inc. | Inhibitors of cysteine proteases and methods of use thereof |
WO2021252644A1 (en) * | 2020-06-09 | 2021-12-16 | Pardes Biosciences, Inc. | Inhibitors of cysteine proteases and methods of use thereof |
WO2022133588A1 (en) * | 2020-12-21 | 2022-06-30 | The Governors Of The University Of Alberta | Rna virus inhibitor compounds and uses thereof |
Non-Patent Citations (5)
Title |
---|
CARREIRAKVAERNO: "Classics in Stereoselective Synthesis", WILEY-VCH: WEINHEIM, 2009 |
GREENEWUTS: "Protective Groups in Organic Synthesis", 2007 |
RAUTIOKUMPULAINEN ET AL., NATURE REVIEWS DRUG DISCOVERY, vol. 7, 2008, pages 255 |
SIMPLICIO ET AL., MOLECULES, vol. 13, 2008, pages 519 |
VUONG WAYNE ET AL: "Improved SARS-CoV-2 Mpro inhibitors based on feline antiviral drug GC376: Structural enhancements, increased solubility, and micellar studies", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 222, 1 October 2021 (2021-10-01), AMSTERDAM, NL, pages 113584, XP093006293, ISSN: 0223-5234, DOI: 10.1016/j.ejmech.2021.113584 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023205779A1 (en) * | 2022-04-22 | 2023-10-26 | Pardes Biosciences, Inc. | Process for making cysteine protease inhibitor intermediates |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10752598B2 (en) | Aryldiazepine derivatives as RSV inhibitors | |
JP6581607B2 (en) | Synthesis of polycyclic carbamoylpyridone compounds. | |
US10647711B2 (en) | Azepin-2-one derivatives as RSV inhibitors | |
CN111343990B (en) | Benzodiazepine-2-one and benzodiazepine-2-one derivatives | |
EP2809660B1 (en) | Macrocyclic compounds for modulating il-17 | |
JP5789260B2 (en) | Method for preparing protease inhibitor of hepatitis C virus | |
WO2021150806A1 (en) | Heterocyclic compounds as anti-viral agents | |
TW201217373A (en) | Prodrug of substituted polycyclic carbamoyl pyridone derivative | |
WO1998018794A1 (en) | Novel heterocyclic amide compounds and medicinal uses thereof | |
WO2014015054A1 (en) | Beta amino acid derivatives as integrin antagonists | |
AU2015269598B2 (en) | Novel quinoline derivatives and their use in neurodegenerative diseases | |
KR20160009052A (en) | Bace inhibitors | |
CA2965512A1 (en) | Trifluoromethyl alcohols as modulators of ror.gamma.t | |
EP4180423A1 (en) | Novel tnf activity inhibitor compound, and pharmaceutically acceptable salt thereof | |
JPH0471073B2 (en) | ||
CN115353508B (en) | 5-pyridine-1H-indazole compound, pharmaceutical composition and application | |
WO2023044509A1 (en) | Process for making cysteine protease inhibitors and compounds provided by that process | |
CN108794517B (en) | Arginase inhibitor and preparation method and application thereof | |
CA3081564A1 (en) | Double-headed protease inhibitor | |
WO1995021163A1 (en) | Pyridonecarboxylic acid derivative substituted by bicyclic amino group, ester thereof, salt thereof, and bicyclic amine as intermediate therefor | |
WO2016023522A2 (en) | Substituted phosphoramidate compounds and uses thereof | |
WO2017004797A1 (en) | Pyrrolidinone compounds | |
WO2017070794A1 (en) | Process for the preparation of 2-[2-(2-amino-2-carboxy-ethylamino)-2-carboxy-ethylamino]-succinic acid (am-a) and analogs and derivatives thereof | |
WO2017005069A1 (en) | Pyrrolidinone compounds | |
RU2794124C2 (en) | Methods for obtaining benzodiazepine derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22793331 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |